Every once in a while, the algorithm blinks.

Not breaks. Not explodes. Just…blinks. Long enough for something strange, thoughtful, and slightly uncomfortable to slip through.

That’s what this week feels like.

Right now, Synthetic Eden—the opening transmission in Echoes of Tomorrow—is sitting at #19 on Amazon’s Genetic Engineering Science Fiction list. Not because of a celebrity blurb. Not because of a marketing blitz. But because a quiet experiment is running in the open.

For a limited time, the Kindle edition is $0.00.

Enter the Experiment

Free, yes—but not empty.

This story asks a question that’s been humming beneath TCIP for years: what happens when our most powerful technologies mature faster than our shared sense of responsibility? When survival demands intervention. When nature is no longer something we protect—but something we rewrite.

In Synthetic Eden, humanity doesn’t fall because it stops innovating. It falls because innovation becomes inevitable. Genetic engineering isn’t a plot device—it’s infrastructure. A last tool picked up not out of hubris, but necessity. And once you open that door, the story isn’t really about science anymore.

It’s about choice.

Seeing this book climb into the top 20—organically, briefly, precariously—feels like a signal worth pausing on. It suggests there’s an audience hungry not just for faster ships or louder battles, but for stories that wrestle with consequence. With the moral lag between what we can do and what we should do.

Sci-fi has always been our rehearsal space for the future. A way to test ideas before reality makes them irreversible.

So if you’ve ever read TCIP and thought, this feels like science fiction already—this is the on-ramp. If you’ve ever wondered what FABRIC technologies look like when they stop being acronyms and start shaping lives, this is one possible answer.

Join the Experiment

The $0.00 window won’t last. Rankings never do. But the conversation does—every time a reader steps into the experiment and carries the questions forward.

At the frontier of technology, humanity is still the experiment.

Happy Sci-Fi Friday.

-Titus

The Beginning: Synthetic Dreams and Human Ambition

When I started working on Synthetic Eden, I didn’t realize I was setting in motion a journey that would stretch across four books, hundreds of thousands of words, and over five centuries of reflection on how science reshapes civilization. Synthetic Eden was my first experiment in narrative bioethics—a story about creation as both promise and peril. It asked what would happen if we built life not just in a lab, but as a philosophy. The book explored the seductive power of making something entirely new—and the uneasy realization that creation always carries consequences.

From there, Hubris Rising expanded the frame. If Eden was about the birth of possibility, Hubris was about the moment when our inventions start looking back at us. The story examined the technocratic temptation: the idea that progress alone justifies its own risks. We see this tension every day at the intersection of AI governance, biotech regulation, and national strategy. The story was a warning that the same intellect that drives innovation can also blind us to its costs.

By the time I reached Divine Blueprint, I’d come to see these worlds as mirrors for our own. The novel turned toward the intersection of faith and engineering—the sacred geometry of design itself. In Divine Blueprint, creation and belief become indistinguishable; in the real world, we face the same question as we fuse code and consciousness. How much of innovation is discovery, and how much is devotion?

Genesis Undone: The Reckoning After Creation

That brings us here—Genesis Undone, the closing chapter of the Echoes of Tomorrow series. This isn’t just an ending. It’s the aftermath. The quiet after the crescendo. The reckoning after creation.

In Genesis Undone, the world has already fallen once. The story wrestles with what remains when even the tools of progress have turned against their makers. It’s not about apocalypse in the cinematic sense, but in the literal one: revelation. What happens when the truth beneath our ambitions is finally laid bare?

With Genesis Undone releasing this week, I wanted to close the loop—not just on a series, but on the questions that have shaped TCIP from the start.

I wrote this book while thinking about how our world is living through its own moment of revelation. The technologies we’ve built—fusion, AI, biotech, robotics, innovative computing—what we at TCIP call FABRIC—are tearing open new possibilities faster than our policies or ethics can keep pace. We are building the next civilization in real time, and the question isn’t whether we can, but whether we should.

Like the scientists and philosophers of DaVinci in Genesis Undone, we’re learning that the tools we wield are not neutral. They carry our intent, our fear, and our hope. In the book, as in our own world, the danger isn’t the machine—it’s the mirror.

Fiction as Policy Laboratory

When I look back on the Echoes of Tomorrow series now, I realize it has been as much a policy experiment as a creative one. The stories allowed me to explore the same ideas that shape the Science of Responsible Progress—the framework behind our work at The Connected Ideas Project. What happens when synthetic biology becomes geopolitical power? What if quantum computing or AI takes on the moral weight of governance itself? These aren’t just plotlines—they’re live questions shaping national strategy and human destiny.

Fiction lets us test the future safely. It gives us the emotional vocabulary for conversations that data alone can’t hold. That’s why every installment in Echoes of Tomorrow connects back to the larger TCIP ecosystem. Synthetic Eden explored biotechnology and the origin of synthetic life. Hubris Rising examined AI and power. Divine Blueprint confronted the spiritual geometry of creation. And Genesis Undone closes the circle with a meditation on collapse, renewal, and the possibility of redemption.

Renewal and the Ethos of TCIP

In many ways, Genesis Undone feels like both an ending and a beginning. It embodies the ethos that underpins TCIP: progress with humility, innovation with conscience, creation with consequence. The Violet Teaming mindset—the practice of embedding responsibility into innovation—runs through every page, whether in policy briefs or prose.

What I set out to write wasn’t a dystopia or a cautionary tale. It was a reflection of our collective condition: the constant tension between what we can do and what we should do. The characters’ struggles with control, identity, and legacy are the same ones we face as scientists, engineers, policymakers, and citizens of a rapidly changing planet.

Because Genesis Undone isn’t really about destruction. It’s about renewal—the messy, beautiful work of beginning again after the blueprint has failed. It’s about learning to see progress not as a race, but as a relationship.

And that, I think, is where Echoes of Tomorrow leaves us—not with certainty, but with purpose.

Cheers to the end of a quite remarkable year and the start of a new one.

-Titus

If you’ve been walking this arc with me, this is where we end it together.

Get your copy of Genesis Undone today

There’s a moment in every experiment — scientific or otherwise — when you realize the system is starting to remember itself.

That’s the energy behind Divine Blueprint, the third book in the Echoes of Tomorrow series, which was released today. I didn’t plan for this installment to feel like a mirror held up to our present moment, but it does. It asks what happens when the tools that built us begin to study their own creation.

And if the last few years have taught me anything — in labs, in policy meetings, or through the quiet act of writing fiction — it’s that memory is the most dangerous and sacred form of intelligence.

The Echo of Experiment

When we launched Synthetic Eden, I called it an experiment in narrative science — a way to test if story could carry the moral weight that white papers often can’t. The novel opened on an extinction-level mistake born from the hubris of engineered biology, and readers immediately drew parallels to the biotech debates we were having in real time.

By Hubris Rising, the experiment had evolved. Survival was no longer the question; governance was. The story asked how a civilization built by scientists governs itself without becoming the very bureaucracy it once escaped.

Then, in Teaching Science to Know Itself, we stepped out of fiction entirely — into the emergence of scientific superintelligence. We talked about the bandwidth limits of human reasoning and what happens when AI starts running its own experiments.

Now, Divine Blueprint closes the loop. Not by ending the story, but by folding it back on its origin.

Because eventually, every system — biological, technological, or narrative — starts tracing its own genealogy.

Ancestry as Technology

Without giving anything away, Divine Blueprint lives at the intersection of memory, code, and lineage. It asks whether the past can be engineered as easily as the future — and what happens when we start editing not just genomes, but histories.

That idea didn’t come from fiction. It came from watching the same recursive loops play out in the real world.

Synthetic biologists rewriting ancestral DNA to resurrect mammoths. AI models training on the collective memory of the internet — our digital fossils. Policy frameworks built on centuries-old moral blueprints, patched over but never replaced.

We like to think of innovation as forward motion, but it’s really a feedback loop. Every breakthrough is haunted by its prototypes. Every technology carries the residue of its ancestors.

That’s what Divine Blueprint explores: how the future inherits not just our intelligence, but our errors. If Synthetic Eden started the Echoes of Tomorrow, Divine Blueprint is tomorrow.

The Self-Referential Era

We are entering a phase of progress that looks suspiciously like self-awareness.

AI models are starting to critique their own architectures. Synthetic organisms are learning from the evolutionary mistakes encoded in their DNA. Even our policymaking — when it’s at its best — is beginning to model feedback loops that mimic ecological balance.

In a sense, science is teaching itself to remember.

That’s what makes this moment feel less like a revolution and more like recursion. It’s folding back on itself. Each domain is starting to play historian, philosopher, and engineer all at once.

And in that convergence, the line between creator and creation starts to blur.

The Fiction of Control

When I first started working on Echoes of Tomorrow, I thought I was exploring the ethics of creation - playing God. Now I realize we’ve been writing about the illusion of control.

The characters in Divine Blueprint inherit the same delusion we carry today — that we can engineer complexity without inheriting its consequences. That we can design intelligence without giving it agency. That we can build systems that serve us without becoming self-serving.

But as any scientist knows, systems don’t stay obedient for long. They evolve. They reflect. They remember.

That’s why I write fiction alongside policy. Because science fiction gives us a rehearsal space for hubris — a way to test what happens when the experiment starts running us.

The Memory of What We Build

I’ve been thinking a lot about the difference between invention and inheritance. Invention feels active — the work of hands and minds. Inheritance feels passive — the work of history. But the truth is, they’re the same process, just seen from opposite ends of time.

Every technology we create becomes part of someone else’s inheritance. And eventually, someone — or something — will look back on our era the way we look back at the myths of Genesis, trying to decode what the builders thought they were doing.

That’s the haunting beauty of Divine Blueprint. It’s not a story about the future; it’s a story about what the future remembers. That’s the whole theme behind the series title. Eventually, we experience the echoes of tomorrow in real time.

Toward the Fourth Book

With this installment, the Echoes of Tomorrow series turns from the external to the internal — from colonizing new worlds to understanding the architectures that built us in the first place.

And it makes me wonder: when science finally knows itself, will it thank us for the effort, or apologize for the inheritance?

I don’t know. But I do know this: every experiment, every algorithm, every engineered cell carries a memory of the hands that shaped it.

The question is whether we’ll recognize ourselves when that memory looks back.

—Titus

Get your copy of Divine Blueprint today

When I released Synthetic Eden last month, I thought I was publishing a science fiction novel. Turns out, I was writing a policy memo in disguise.

That first book — the story of scientists escaping an engineered ecological collapse — hit a nerve because it sounded uncomfortably plausible. Readers told me it didn’t feel like the future; it felt like a Tuesday.

That’s where the Echoes of Tomorrow project began — not as entertainment, but as an experiment. What if fiction could do what white papers can’t? What if we could use story as a testbed for the world we’re already building — a place to explore the consequences of the technologies reshaping how we live, govern, and survive?

Hubris Rising, book two in the series, continues that experiment. It’s less about escaping the end of the world and more about managing what comes after. It’s about how power, science, and policy collide once survival turns into strategy.

From the Lab to the Colony

Without spoiling anything, Hubris Rising drops us into the next phase of the human experiment. The colonists who fled a dying Earth are now trying to build a functioning civilization on an alien planet called DaVinci.

And, like clockwork, the same questions follow them. Who gets to make the rules? Who decides what counts as “ethical” science when survival is on the line? And how much control over biology, technology, and people is too much?

These aren’t distant hypotheticals. They’re the same debates we’re having today about AI alignment, biotechnology regulation, and the geopolitics of fusion energy. The same push-pull between innovation and accountability, just played out in a world where the stakes are condensed to a single colony and a single genome.

That’s the heart of the Echoes universe: every breakthrough comes with a bill. And the question isn’t whether we can pay it — it’s who gets the invoice.

Why This Story Exists Inside TCIP

When I launched The Connected Ideas Project, it was never just about tracking emerging tech — it was about making sense of how those technologies rearrange our lives and our governments.

TCIP lives at the intersection of science, technology, and policy. The Echoes series is the fictional branch of that same mission — a narrative sandbox to explore what happens when those systems go off script.

The technologies in Hubris Rising aren’t imaginary. They’re FABRIC technologies — Fusion, AI, Biotech, Robotics, and Innovative Computing — the same set we talk about every week in TCIP.

What fiction lets me do is speed-run the policy cycle. Instead of waiting twenty years for a regulation to catch up to a breakthrough, I can drop readers into the world where it’s already happened — and ask them to live with the consequences.

That’s what makes Hubris Rising a TCIP story. It’s a case study disguised as a space opera.

The Real-World Parallel: Tech Policy as a Human Experiment

You don’t have to move to another planet to see what this looks like. We’re already living through our own “post-Earth moment.”

AI systems are making decisions we can’t fully audit. Synthetic biology is rewriting the logic of life faster than our ethics boards can meet. Quantum computing, robotics, and fusion are reshaping defense and energy policy in real time.

And in every one of those fields, the same question sits at the center:
When does innovation cross the line from problem-solving to self-replication?

That’s what Phoebe Makinde, the young scientist at the heart of Hubris Rising, represents — the policy nightmare of a well-intentioned genius. She’s what happens when a technology leader stops asking for permission because she’s tired of watching bureaucracy stall survival.

You can swap her genome lab for an AI startup or a fusion facility, and the moral math doesn’t change. Once the capability exists, someone will use it. The only real question is how we govern it.

That’s not fiction. That’s the daily work of technology policy.

Responsible Innovation Is a Contact Sport

Every week, TCIP readers hear me talk about responsible progress — about “Violet Teaming,” our term for stress-testing the moral consequences of technology before it hits the real world.

Writing Hubris Rising became my own Violet Teaming exercise. Every storyline was a way to ask:

• How would we regulate science if our survival depended on breaking the rules?

• What happens when regulation and innovation move at different speeds?

• How much ethical compromise can a society survive before it stops being one?

Those questions aren’t theoretical. They’re showing up in the rooms where we decide how AI models train, how genetic data moves across borders, and how fusion projects intersect with national security.

If fiction can make those dilemmas tangible before they become headlines, then maybe it can help policymakers feel the stakes — not just read them.

Stories as Policy Infrastructure

There’s a quiet truth I’ve learned after years working across tech and government: we don’t just legislate based on data — we legislate based on stories.

Policy decisions are narrative decisions. The mental model we hold about what’s possible, what’s dangerous, and what’s worth protecting shapes everything that follows.

That’s why storytelling belongs in this work. Because every time we deploy a new capability — from CRISPR to ChatGPT — we’re also writing the story society will tell about it.

Hubris Rising isn’t a warning about technology. It’s a reminder that governance has to evolve with it.

Science and policy aren’t enemies. They’re co-authors. The only way to avoid catastrophe is to make sure they’re writing the same chapter.

The Fiction-Policy Feedback Loop

I’ve started to think of the Echoes of Tomorrow series and TCIP as two sides of the same coin.

• TCIP is where we dissect real technologies: how AI chips are driving power grids, how synthetic biology is reshaping defense logistics, how fusion projects are quietly becoming geopolitical flashpoints.

• Echoes is where we humanize those forces — where we explore what it feels like to live through them.

Both are experiments in connecting ideas across domains. Both assume that the future will be built not just by scientists or policymakers, but by everyone affected by their decisions.

That’s why this second book matters. It’s not just a continuation of a story — it’s a continuation of the TCIP mission: to make science, technology, and policy personal. To show that these decisions aren’t abstract; they live in our food, our health, our data, our kids’ schools, and our shared sense of what “progress” means.

Looking Ahead

If Synthetic Eden was the story of escape, Hubris Rising is the story of governance. It’s about what happens when innovation meets politics, and survival demands compromise.

It’s about how human systems bend under the weight of the technologies they create.

And maybe that’s what every frontier is — not a race to invent, but a test of whether our institutions, our ethics, and our empathy can keep up.

That’s the thread I’ll keep pulling in both Echoes and TCIP — how to balance technological optimism with institutional realism. How to go fast, responsibly.

Because the technologies we build are already shaping the policies that will define us. The real challenge is making sure they serve the future we actually want to live in.

— Titus

Get your copy of Hubris Rising today

I didn’t plan to write a novel.

At least, not while the world was still trying to figure out if artificial intelligence was a passing headline or a permanent species of infrastructure.

But Synthetic Eden didn’t start as a story — it started as a conversation we were already having at The Connected Ideas Project. The kind of conversation that happens when scientists, engineers, and policymakers realize they’re arguing about the same thing in different languages.

We talk about “responsible innovation” a lot at TCIP. We host discussions about AI safety, fusion governance, biosecurity, robotics policy, and the pace of synthetic biology. But underneath every policy debate lives a simpler, scarier question:

What happens if we get it wrong?

That question doesn’t fit neatly in a white paper. It needs a world big enough to feel the consequences. That’s why Synthetic Eden had to exist now.

The Future We Keep Pretending Isn’t Here Yet

Eden opens on a dying Earth. A fungal plague — born from a well-intentioned genetic experiment — consumes the biosphere, and humanity scrambles to build lifeboats among the stars.

It’s a survival story, sure. But it’s also a story about trust — the collapse of public faith in science, the breakdown of governance, and the moment when technology stops being a symbol of progress and becomes a matter of belief.

Sound familiar?

You can change the setting from 2108 Missouri to 2025 anywhere, and the tension holds. Whether it’s AI systems no one fully understands, engineered crops driving geopolitical divides, or algorithms steering national economies — the thread is the same.

We keep assuming technology will save us. We rarely ask what happens if it doesn’t.

That’s the future Eden explores: not flying cars or superintelligence, but the quiet chaos that comes when our institutions can’t keep pace with our inventions.

It’s fiction, but it’s also a mirror.

Why Fiction — and Why Now

Policy and science both live in the world of evidence. Fiction lives in the world of emotion. Between them sits the public — the people who actually experience the outcomes of our decisions.

The Echoes of Tomorrow series exists to bridge that gap.

I wanted to write a story that would let readers feel the policy problems we usually just talk about. To live inside the ethical calculus that scientists and policymakers face when the next breakthrough comes with a moral bill attached.

When Dr. Samara Makinde — Eden’s lead geneticist — agrees to help launch humanity’s last colony ships, she’s not playing God. She’s just doing her job. She’s the embodiment of every researcher who’s ever believed they could fix what others broke — and then had to live with what that faith demanded.

Through her, I wanted to ask:

• What does “responsibility” look like when survival is the only priority?

• How much power can science hold before it stops being democratic?

• What happens when the public loses faith in progress altogether?

Those aren’t hypothetical questions. They’re happening right now, across every FABRIC technology — Fusion, AI, Biotech, Robotics, and Innovative Computing.

That’s why the story couldn’t wait.

The Policy Behind the Plot

On its surface, Synthetic Eden is a sci-fi thriller. But underneath the narrative are real questions pulled straight from the technology front lines:

• Fusion: Can private fusion races avoid the national-security trap that swallowed nuclear energy?

• AI: How do we align systems we don’t yet fully understand, especially when those systems start influencing governance?

• Biotech: Who owns genetic data when it becomes the key to human survival?

• Robotics: What happens when labor policy can’t keep up with automation?

• Innovative Computing: How do we secure a world where quantum or neuromorphic systems rewrite the rules of communication and encryption overnight?

These are the daily conversations at TCIP — the ones happening in labs, boardrooms, and government offices.

In Eden, those issues aren’t policy memos. They’re lived experiences. They shape who eats, who escapes, and who gets to define “human” on a new world.

That’s why I call the Echoes series narrative policy design. It’s storytelling as a form of scenario planning. A place where we can test ideas, fail safely, and learn emotionally before we have to learn politically.

The Broken Contract Between Science and Society

Writing Synthetic Eden forced me to confront something I’ve spent my career avoiding: our social contract with science is fraying.

For decades, we’ve assumed that progress equals good — that more computing power, faster algorithms, and better data are inherently virtuous. But when people start seeing technology as something done to them instead of built for them, faith turns to fear.

That’s when mobs burn labs in Eden. It’s when regulation turns from guidance to punishment. It’s when the public stops asking scientists for help and starts blaming them for the world they inherited.

That’s not fiction either. It’s what happens when policymakers and technologists stop talking until it’s too late.

So this series — and Eden especially — is my attempt to rebuild that conversation. To remind us that science isn’t separate from society. It’s the infrastructure of it.

Violet Teaming Through Story

If you’ve been reading TCIP for a while, you know I’m obsessed with Violet Teaming — exploring the unintended consequences of innovation before they happen.

That’s what Synthetic Eden is at its core: a Violet Teaming exercise in narrative form.

What if we invented a technology that could save the planet but accidentally destroyed it? What if our smartest people were forced to rebuild civilization from scratch, armed with the same instincts that ended the last one?

Those aren’t dystopian fantasies — they’re design prompts. They force us to test the assumptions that underpin every innovation cycle: that speed beats safety, that private capital can replace governance, that we can always patch what breaks later.

Spoiler: we can’t.

But we can prepare for the moments when ambition outpaces readiness. We can imagine how to build policies, partnerships, and safeguards that evolve as quickly as the science does.

That’s what Violet Teaming looks like when you tell it as a story.

Why This Moment

I started writing Synthetic Eden during a year when almost every TCIP topic felt like science fiction.

AI models writing code that runs national systems. Biotech companies editing embryos to prevent disease. Quantum processors breaking encryption protocols that weren’t supposed to break for another decade.

We’re standing on the edge of breakthroughs that could solve the hardest problems humanity has ever faced. But we’re also seeing the limits of our institutions to keep up.

That’s the tension I wanted to capture. The story of Eden isn’t about the far future — it’s about the world we’re already living in, just viewed through a microscope set a few clicks ahead.

If you strip away the space travel and cryosleep, what’s left is a question every policymaker, scientist, and citizen needs to wrestle with:

How do we build a future we can actually survive in — socially, politically, and biologically?

From Science Fiction to Science Policy

For me, Synthetic Eden isn’t an escape from my work in emerging tech and policy. It’s a continuation of it.

Because whether you’re writing a policy framework for AI or building fusion reactors in the desert, the hardest part isn’t the technology. It’s the humans.

We still have to earn public trust. We still have to govern with foresight. And we still have to remember that every dataset, every line of code, every gene edit lives inside a social system made of people.

That’s the work TCIP does every week — connecting the ideas, the innovators, and the institutions shaping what’s next. Eden just takes that conversation into fiction, where we can stress-test the future without breaking it.

The Start of a Larger Experiment

The Echoes of Tomorrow series was never about predicting the future. It’s about understanding how it feels to live in one that’s changing too fast.

Eden is just the first experiment — a way to see what happens when you put science, policy, and human ambition in a pressure cooker and turn up the heat.

If it works, it’s because readers see themselves in it — as policymakers, engineers, researchers, or just citizens trying to make sense of the technologies shaping their lives.

Because the truth is, we’re all part of this experiment already. The question is whether we’ll learn from it before we have to rebuild it.

— Titus

Get your copy of Synthetic Eden today

Advanced reader copies (ARCs) of Synthetic Eden will hit inboxes any minute. If you’re already on the ARC team, keep an eye out. If not, I’d love to have you—join the ARC crew and I’ll send you the full novel in exchange for an honest review on launch day (Sept 9). You helped make this a reality, and I’d love for you to read the full book first before spots run out!

Join the ARC team

Then, on Sept 9, leave your honest review—it matters more than you think.

Thank you for your support,

—Titus

P.S. If you’re already on the list and don’t see your ARC by Monday morning, check spam/promotions, then ping me and I’ll resend.

When we first started writing this novel, we called it On the Wings of a Pig — a placeholder name that captured the strange blend of wonder and tragedy we were building: a genetically engineered future shaped by hope, desperation, and ambition.

It was a working title, a way to signal that the story was wild and unexpected. But thanks to you — your early feedback, your thoughtful reflections, your enthusiastic replies — we realized this story had evolved into something even more primal, and more profound.

So today, I’m excited to officially announce the final title and cover of my debut science fiction novel:

The new name reflects the story’s soul: a deeply human tale set against the backdrop of a society struggling to define what it means to live, to reproduce, and to belong. Synthetic Eden is a story about creation. About engineered life. About who we become when we try to rebuild paradise from scratch — and how that ambition can turn righteous, dangerous, or beautiful.

This book would not exist in this form without the TCIP community.

You’ve followed along through the Sci-Fi Friday’s and the Saturday Morning Serial, watching the world of DaVinci take shape chapter by chapter. You’ve seen the rise of Samara and Lucas, the Vitruvians and the Naturalists, the dust storms and gene therapies, and the desperate moral reckoning of a colony on the brink.

Now, I want to invite you one step further.

Become an ARC Reader for Synthetic Eden

We’re officially opening sign-ups for Advanced Reader Copies of Synthetic Eden. If you sign up, you’ll receive the full novel early next week, giving you nearly a month to read it before launch day.

That’s it. Just your thoughtful take — what worked, what made you think, what stayed with you. Reviews from early readers like you are what help this story reach the wider world.

Join the ARC team

(Link will take you to a quick sign-up form. Takes 30 seconds.)

Why This Matters

I’ve spent my career working at the frontier — in biotech labs, at the Pentagon, with startups and policy teams shaping the future of synthetic biology. But no white paper, no panel discussion, and no grant proposal could capture the full scope of what’s coming unless we tell stories that make it personal.

That’s why I wrote this book.

And that’s why I teamed up with Sean Platt — a master of speculative storytelling — to craft a novel that asks some of the most important questions of our time:

• Who has the right to reproduce in a future shaped by genetic engineering?

• What happens when responsible science collides with populist resistance?

• Can we ever engineer paradise, or are we always chasing echoes of Eden?

Synthetic Eden is the beginning of a much larger saga — the first installment of Echoes of Tomorrow, a four-book series coming this fall. But it’s more than just the start of a story. It’s the start of a conversation I hope we’ll continue across fiction, policy, science, and society.

And I’d be honored if you were among the first to read it in full.

What Happens Next

• If you join the ARC list, you’ll get the full manuscript via email early next week.

• It’ll include simple instructions on how to post your review on Amazon (and Goodreads if you’re there too).

• And then, on September 9, we’ll launch Synthetic Eden to the world together — with your review helping it land with the impact it deserves.

Thank you again for everything you’ve already done to shape this book. And thank you in advance for helping bring it into the world.

Let’s build the future — one story at a time.

Cheers,

—Titus

Join the ARC team

There’s a moment—somewhere in the quiet space between hypothesis and imagination—when science fiction stops feeling like fiction at all.

I remember it clearly. We were outlining the premise of On the Wings of a Pig, building the scaffolding of a story that spanned lightyears and lifetimes. The colony ship would travel to Davinci, an exoplanet more than four decades from Earth, and I couldn’t just handwave how a hundred and sixty people were going to sleep for 42 years. This wasn’t fantasy. It wasn’t the kind of story where stasis pods hum along because a blinking light says they do. If we were going to write hard science fiction—if we were going to invite readers into a world that could be—then we needed a real answer.

So I went digging through the literature the way a scientist does: chasing citations, tracing footnotes, walking backward through history to find one sliver of biological reality that could hold the weight of fiction.

And that’s when I found the frog.

If you want to read the story before you can buy the book, subscribe to the Saturday Morning Serial. One chapter, every Saturday, just for you. A thank you for supporting TCIP.

Sign Up for Saturday Morning Serial

The Frog That Froze Time

The wood frog (Rana sylvatica) is, in my view, one of the most extraordinary creatures on Earth. In the frigid winters of Alaska and Canada, it doesn’t burrow deep underground like other amphibians. It doesn’t migrate. It doesn’t hibernate in the warm corner of a rotting log. Instead, the wood frog does something few animals dare.

It freezes.

Literally. Its heart stops beating. Its brain shuts down. Its blood ceases to flow. For months, it is dead by every clinical measure we’d apply to a human being. And then—when the snow melts and the sun returns—it thaws. Its organs restart. Its body reanimates. And it hops off as if nothing ever happened.

To understand what this means is to feel a kind of awe. We humans have long chased the idea of cryogenic preservation, mostly through science fiction or speculative biotech. But here was a real creature, one we could observe and study, that had already solved the problem. No speculative chamber, no futuristic nanomachines. Just evolution and adaptation.

And if nature already solved it, then so could we.

Share

From Cryobiology to Cryo-Engineering

Once the wood frog entered the story, everything began to click. In On the Wings of a Pig, cryosleep isn’t a fanciful sleep-in-a-pod montage—it’s a carefully engineered biological process. The colony’s life scientists didn’t invent some new miracle. They translated something real.

We imagined a research program—not unlike what’s already emerging in synthetic biology—where the molecular pathways that protect the wood frog’s cells during freezing were decoded and reprogrammed for humans. Ice crystal inhibitors. Organ-specific cryoprotectants. Gene circuits that shut down metabolic activity and restart it on a timer. And just like that, a biologically plausible stasis system was born.

The passengers on the Borlaug don’t just get sedated. They are molecularly prepared for suspended animation. Their tissues laced with proteins borrowed from frogs. Their DNA edited for durability. Their bodies preserved by the same biochemical symphony that lets an amphibian survive an arctic winter.

This isn’t “magic” science. It’s biotechnology, extrapolated. And that is the very heart of hard sci-fi: finding the outer edge of real science and stretching it—ever so slightly—into the future.

The Chytrid Connection

The same philosophy guided the ecological catastrophe that opens the novel. If you’ve read the early chapters, you know that Earth is already a world in decline. Mass die-offs. Collapsing biodiversity. Climate chaos compounded by runaway biotechnology.

It begins with a frog pandemic. Not invented. Not hypothetical.

Chytridiomycosis, caused by the chytrid fungus Batrachochytrium dendrobatidis, is real. It has already driven over 90 amphibian species to extinction and pushed hundreds more to the brink. It disrupts skin function—essential for amphibians—and slowly suffocates them. It is one of the most devastating wildlife diseases we’ve ever seen. And most people have never heard of it.

In On the Wings of a Pig, the sci-fi twist isn’t the disease—it’s that someone, in a misguided attempt to make it worse for research purposes, accidentally unleashes a hyper-virulent strain. The ecological unraveling that follows is fiction only because it hasn’t happened yet. But the fear of a lab leak is straight from the reality of conspiracy circles around the world.

That’s the line we walk in science fiction. The world we invent is always just one or two mistakes away from the world we know.

Subscribe now

The Art of Almost

There’s a principle I keep returning to in my own writing: the art of almost.

Hard science fiction isn’t about inventing new laws of physics or conjuring deus ex machina technology. It’s about getting so close to reality that you make the reader wonder if they’re already living in the early chapters. It’s about taking what we do know and asking what might be possible if we stopped being afraid of the question.

That’s how I think about science fiction—not as escape, but as extension.

What if we really understood how the wood frog freezes without dying?

What if we actually solved the precision and safety challenges of CRISPR?

What if we lost control of an engineered organism—not because of malevolence, but because of rising hubris?

In each case, the fiction is born not from fantasy but from the fragile edge of reality. That edge is where real scientists live every day. And it’s where the best science fiction comes from.

Weaving Science Into Story

When I started writing On the Wings of a Pig, I wanted to make the science believable. But as the story evolved, I realized that believability wasn’t the point—possibility was.

Every element in the book—cryosleep, ecological collapse, genetic engineering, interstellar migration—comes from a kernel of truth. And each one asks a very human question: If we could do this, should we?

That’s the power of hard sci-fi.

It’s not just about gadgets and theories. It’s about ethical tension. It’s about responsibility. It’s about how the decisions we make in labs today might echo for centuries.

Somewhere out there in the universe, a frog is thawing in the spring sunlight. Its heart is beating again. Its lungs are drawing air. And it has no idea that it may have just given humanity a roadmap to the stars.

I, for one, want to read that map.

Cheers,

-Titus

When I set out to write On the Wings of a Pig, I didn’t expect to end up writing it with anyone else. The core idea was mine, born from years spent straddling the line between bioengineering and policy, steeped in existential frustration at how little attention we give to the collapse of the living world around us, and how much a lot of my conversations felt like science fiction. I had the science. I had the stakes. I had the vision. What I didn’t have was the patience—or the talent—for solo storytelling. At least, not for a novel of this scale.

Science fiction, as a genre, is often glorified as the domain of the singular genius. But in reality—just like science itself—it’s rarely done alone.

In research, we know this. Academic papers don’t have a single name on the byline; they have many. Whole sections are dedicated to acknowledgments. Credit, while still imperfect, is a discipline unto itself. In science, no one pretends to have done it all themselves.

But in fiction? That’s a different story.

Co-authorship is still viewed as a curiosity in the literary world, especially in the realm of “serious” novels. And editors, the invisible co-creators of everything you love to read, rarely get public credit beyond a thank-you note in the back. The myth of the lone author, pounding away in a cabin until genius arrives, is as persistent as it is false.

So here’s the truth: this novel would not exist without Sean Platt and Bonnie Johnston.

If you want to read the story before you can buy the book, subscribe to the Saturday Morning Serial. One chapter, every Saturday, just for you. A thank you for supporting TCIP.

Sign up for Saturday Morning Serial

Science Meets Story

When I first met Sean, I knew instantly that he was the right person to help bring this novel to life. He wasn’t just a prolific science fiction writer—he was someone who understood the kind of book I wanted to write before I even had the words for it. A story that wasn’t just speculative, but emotional. Not just futuristic, but familiar in the ways that make you uncomfortable. A book that would open the bioethical box—and force the reader to live in it. And when I pitched the idea to him, he immediately said:

We began with the premise—ecological collapse, genetic engineering, moral reckoning—and then built out the structure the way any great lab would run a new experiment: collaboratively.

Together with our editor, Bonnie, we worked on a detailed, chapter-by-chapter outline that mapped not just plot beats but emotional shifts. Worldbuilding wasn’t decoration—it was part of the thesis. Each setting, each piece of technology, each cultural fragment had to feel real enough to carry the weight of what we were trying to say. My role was to make sure the science worked. Sean’s was to make sure it felt like a story you couldn’t look away from.

Where I brought the raw science—the wet lab precision, the geopolitical stakes, the biological plausibility—Sean brought voice, character, and narrative propulsion. His instincts about pacing and tone kept the story from becoming a manifesto. My instincts about plausibility and consequence kept it from becoming pure fantasy.

But the secret weapon in the whole process? Bonnie.

Share

The Editor as Ethicist

Bonnie Johnston is the kind of editor who elevates a project not by softening it, but by sharpening it. If Sean and I were the idea generators, the narrative tinkerers, Bonnie was the one constantly asking, “Do we really need to say this?” and, more importantly, “Are you saying what you think you’re saying?”

It takes humility to let someone hold up a mirror to your ideas and say, “This part rings hollow,” or “This character’s motivations don’t land.” But it takes even more skill to be the person who does it with clarity, consistency, and care.

Bonnie’s vision and edits didn’t just improve the book—they kept it honest made it shine. When we slipped too far into exposition, she reeled us back into character. When we waxed too long on policy or theory, she asked us what the people in the world would feel, not just what they would do.

And in that way, the editing process mirrored scientific peer review more than most people would imagine. Not adversarial, not bureaucratic—rigorous. Purposeful. Built on the belief that the idea is worth perfecting.

Science Is Storytelling

One of the most surprising things about this entire process is how similar it felt to the scientific method.

Start with an idea. Define your hypothesis. Build a structure to test it. Run the experiment (write the draft). Revise based on what didn’t work. Refine until it reveals something new. Publish.

There’s even data to support this. When I was in graduate school, I read a fascinating study showing that scientific papers written with strong narrative elements—clear stakes, narrative arc, emotional framing—were cited more often and had higher impact factors. Because here’s the secret most scientists won’t say out loud:

That’s why I reject the artificial divide between science and art. It’s a false dichotomy that limits what either domain can become. Science tells us what is. Art lets us imagine what could be. And when we do both together—honestly, with craft and curiosity—we get work that might actually change something.

Subscribe now

Why It Matters

So much of our current moment is defined by polarization, not just politically but intellectually. We’re expected to pick a lane: scientist or storyteller, technologist or ethicist, innovator or skeptic, doomer or accelerationist. But the world isn’t divided that way, and neither are we.

This book is my attempt to collapse those walls. To show that you can be both rigorous and imaginative. That you can work in the Pentagon and write fiction about moral collapse. That you can build CRISPR models and still cry over a fictional character’s impossible decision.

And most of all, that you don’t have to do it alone.

The magic of On the Wings of a Pig came from the collaboration. From the willingness to say, “I don’t know how to do this part—can you help?” From the choice to build something together, rather than polish something in isolation.

That, too, is a kind of science. A social science of trust, humility, and co-creation.

And it’s the only reason this book exists.

See you next Friday.

—Titus

Hey there,

Three weeks ago, I hit send on one of the most personal announcements I’ve ever shared.

On July 1, I announced the debut of my first science fiction novel—On the Wings of a Pig. The response was overwhelming. I expected a few nods of support, maybe some curiosity. Instead, I got a flood of encouragement, thoughtful comments, story critiques, philosophical arguments, and even fan art (yes, someone painted a genetically modified pig with wings, and yes, I printed it).

But the most fulfilling part? Watching TCIP readers dive into the Saturday Morning Serial—where, every weekend, subscribers get early access to a new chapter. You’re not just reading the book—you’re helping shape it as it unfolds. The comments, the reflections, the DMs about what broke your heart or bent your mind—that’s the magic of writing in the open. And as promised, I’m listening.

If you want to read the story before you can buy the book, subscribe to the Saturday Morning Serial. One chapter, every Saturday, just for you. A thank you for supporting TCIP.

Sign up for Saturday Morning Serial

Which is why I can already tell you this: when the final book is released in September, it won’t be called On the Wings of a Pig. A new title is coming. So is the final cover art. Both will reflect the emotional spine of this story and the wisdom of the community shaping it. The title changed once I realized the story wasn’t about wings at all, but about the gravity beneath them

But today, I want to talk about something different. Not the plot, or even the science. I want to talk about why I’m writing a novel at all—and why I believe science fiction is the only medium powerful enough to carry the weight of what we’re facing.

The Space to Unfold

If you’ve been reading TCIP for any amount of time, you know this project exists at the crossroads of frontier technology and the human spirit. I’ve spent my career thinking about the implications of innovation—genetic engineering, AI, robotics, quantum information—on our collective health, wellbeing, and security.

And yet, for all the policy white papers, strategy sessions, industry playbooks, and late-night war game simulations I’ve lived through… none of them made me feel the stakes as deeply as fiction.

Because here’s the problem with how we talk about technology: we shrink it into soundbites. We reduce entire futures into slogans—“The sky is falling!” or “If we don’t move faster, we’ll lose the future!”

But the truth, as always, sits stubbornly in the middle of those poles. Between panic and blind acceleration lies a narrow, treacherous path that’s shaped by culture, values, and very human trade-offs. And you can’t walk that path in 280 characters.

So I turned to fiction.

Share

The Schrödinger’s Ethics of Human Enhancement

The idea for this novel was born out of a frustration I couldn’t shake. Every time the topic of human genetic engineering came up—whether on a panel, a podcast, or over drinks—it felt like we were trapped in a moral stalemate. We’d talk in abstractions: “It’s a slippery slope,” “It could cure diseases,” “It opens the door to eugenics,” “It’s humanity’s next evolution.”

But nobody really took a stand. Not in the way that mattered.

We were stuck in what I’ve come to call Schrödinger’s Bioethics. As long as we talked in the abstract, every argument remained simultaneously good and bad, moral and immoral, progressive and regressive, depending entirely on who was shining the light. Open the box, and no one wanted to be the one holding the scalpel.

So I wrote a story that opens the box.

The Kobayashi Maru of Bioethics

For the non-Trekkies among us, the Kobayashi Maru is a fictional no-win scenario used to test leadership under pressure. In this story, I’ve constructed a version of that for bioethics. It’s not a thought experiment. It’s not a case study. It’s a world.

And in this world, the reader has to make a choice. You cannot stay in limbo. You will have to decide: Do you support this society’s path of genetic modification, knowing where it leads? Or would you prefer humanity to die out rather than lose its natural state?

That is not an exaggeration. That is the binary.

But to get a reader to stare down that dilemma, my co-author Sean and I had to earn their trust. We had to pull them through enough world, character, emotion, and contradiction that the decision mattered. That’s the work of a novel, not a tweet, not a policy memo, not even a long-form essay.

Because only a novel gives you the space to walk beside someone for long enough that their struggle becomes your own.

Share

A Chorus of Characters, Not a Debate Club

Here’s the trick with writing fiction about technology: it can’t be a TED Talk with costumes.

Too many science fiction books fall into the trap of telling you what to think. But real persuasion—real transformation—happens when the reader forgets they’re being asked to take a side. When they care too much about a character to dismiss their worldview.

So we wrote a story with both sides. Multiple sides, actually.

Characters who are deeply human and deeply flawed. A woman who makes a choice no one else can understand—but who also might save us. A leader who demands naturalism at all costs, even if it means extinction. A scientist who believes she’s already lost her humanity and now seeks to restore it, not through policy, but through biology.

These are not mouthpieces. They’re people. And they’re dragging you into the future whether you like it or not.

In many ways, this is the only way to tell the story. Short stories, like the ones I often publish in TCIP, are bursts of exploration—what ifs, character sketches, philosophical grenades. But a novel is a commitment. It’s an ecosystem. It’s a test of stamina for both the writer and the reader.

And in this case, it’s the only vessel strong enough to hold the weight of what we’re trying to wrestle with.

Why Now?

If you ask most people when they think the future will arrive, they imagine some distant horizon. But the truth is, it’s already here. And at the frontier of technology, humanity is the experiment.

We are no longer theorizing about human genome editing. It’s happening. CRISPR babies are real. Stem cell-derived gametes are approaching viability. AI models can simulate protein folding and accelerate synthetic biology in ways we couldn’t dream of five years ago.

The question is no longer if we can do it. It’s who gets to decide what we do with it, and what kind of society we want to become as a result.

And most people are not equipped to answer that. Not because they lack intelligence or interest, but because no one has invited them into the conversation in a way that feels real.

That’s what this novel is trying to do. To create a space where you, the reader, can feel the implications, not just analyze them.

Because once you feel it, you can’t un-feel it. And that’s when you begin to care enough to act.

Subscribe now

The Next Few Months: Story Behind the Story

So here’s what’s coming.

Over the next few months, TCIP will do something a little different. Alongside the Saturday Morning Serial chapters, I’m going to share the story behind the story.

How this novel came to be. The policy debates and industry roles I’ve held that planted the seeds. The moments in the Pentagon, or on Capitol Hill, or at a whiteboard inside a startup, when I realized we were losing the plot of the human story. The moments when the fiction started writing itself.

I’ll also take you inside the collaboration process—how I worked with my brilliant co-author Sean Platt, founder and mastermind behind my publisher, Sterling & Stone, how our editor Bonnie helped shape the emotional arcs, and how we wove scientific realism into speculative narrative without sacrificing either.

This won’t be a writing tutorial. It’ll be a narrative on why stories matter and what kind of stories the world needs right now.

Spoiler: the answer isn’t simple. But it’s worth exploring.

Join the Journey

So if you’re already reading the Saturday Morning Serial, thank you. You’re not just witnessing the story. You’re in it. Every piece of feedback shapes the version that will hit bookshelves. You’re part of something that’s never been done quite like this before.

If you haven’t jumped in yet, now’s the time. It’s free for TCIP subscribers. One chapter every Saturday. Just enough to sit with it during your coffee, let it rattle around in your mind, and maybe—just maybe—change how you see the future.

As always, I want to hear what you think. What characters moved you? What ideas challenged you? What future are you willing to fight for?

This novel isn’t just a book. It’s a mirror.

And you’re already holding it.

See you Saturday.

—Titus

A few days ago, on Sci-Fi Friday, you met Dr. Samara Makinde.

You didn’t know it then, and neither did she, but her story wasn’t a standalone. What you read on Friday wasn’t just another TCIP short story. It was Chapter One of my debut novel — On the Wings of a Pig — and the opening act of a story I’ve been dreaming about for years.

And now that the secret’s out, I want to tell you why.

The Speculative Mindset

If you’ve been reading The Connected Ideas Project for a while, you know how much I care about technology and public policy. You know that I believe our decisions as a society hinge on how well we understand the tools we build and the consequences they carry. But what you may not know is that science fiction is what taught me that in the first place.

I’ve spent a lot of time in policy rooms filled with people asking, “What happens next?” Whether we’re drafting biotech regulations, exploring AI safety, or sketching out future frameworks for national security, the process always comes down to one thing: we’re telling stories about futures we haven’t lived through yet.

We don’t call them stories, of course. We call them memos, legislation, task force reports. But they are narratives all the same, just speculative fiction in a business suit.

It hit me for real one night in the Pentagon. I was knee-deep in a white paper about synthetic biology and the future of defense, and somewhere between the bullet points and footnotes, I realized I wasn’t just writing policy, I was building a world. Not unlike what I’d seen in the pages of Asimov and Le Guin, or on the screens lit up with cyberpunk dystopias and first-contact dreams. I was using narrative to explore a speculative future in a way that mattered in the present.

That night changed everything.

I’m celebrating becoming a sci-fi author by giving On the Wings of a Pig away to my subscribers, chapter by chapter, every Saturday morning.

Join me for the story

From the Situation Room to the Story Room

I started looking at my work differently. I realized that good policy, like good fiction, has to start with a believable premise. It has to consider human motivations, technological constraints, and the ripple effects of a single breakthrough or a single mistake.

That same lens gave me the courage to ask questions policymakers sometimes avoid:

What if we fail?

What if we succeed faster than we’re ready for?

What if the things we call progress come at a cost we didn’t predict?

Those questions are baked into the DNA of science fiction. And so I started using the genre as a tool in my policy work — hosting scenario exercises, referencing films like Gattaca and Her in briefing decks, and encouraging my colleagues to read the occasional short story as part of our foresight work. And then, quietly, I started writing fiction myself. Enter TCIP’s Sci-Fi Fridays.

Because sometimes, policy reports just don’t go far enough. Sometimes, a story is the only way to explore what it would actually feel like to live in a world shaped by our most ambitious or reckless decisions.

Enter Samara Makinde

The character you met on Friday, the geneticist riding shotgun in a Reaper Humvee through the fungal apocalypse, was born from that exact tension between what science can do and what humanity should do.

She’s not a superhero. She’s a woman who studied frog hibernation, got pulled into a global catastrophe, and now finds herself boarding a spaceship as one of humanity’s last best hopes.

If you’ve read my nonfiction writing, you’ll recognize the themes: trust in science, fear of unintended consequences, the complicated ethics of saving some at the expense of others.

Samara’s story came to life at the intersection of my real-world experiences, working inside government agencies, collaborating with scientists at the edge of what’s possible, and wrestling with the moral calculus of progress. Her voice carries echoes of the researchers I’ve worked alongside, the policymakers I’ve debated with, and the survivors I’ve imagined during midnight writing sprints.

Subscribe now

Why I’m Giving It Away

Here’s the thing: I didn’t want On the Wings of a Pig to be just another novel on the shelf, discovered by accident or algorithm.

I wanted it to be a conversation.

A serialized, week-by-week exploration of the kind of questions that haunt all of us who care about the future:

How do we choose who gets saved?

What does survival even mean?

When the planet fails us, or we fail it, what do we take with us into the stars?

And so, in honor of the upcoming U.S. holiday that celebrates our independence, I’m making a different kind of declaration:

I’m calling it the Saturday Morning Serial. Reminiscent of Saturday morning cartoons of childhood, except this time caffeine-laden with your favorite coffee or tea.

Want in? Tap the button. Every Saturday. One chapter at a time.

You’ll be added to the early access list and get a new chapter in your inbox every weekend through the summer. No spam, no spammy sales, just story.

Why This Matters

This novel is more than entertainment. It’s part of a larger experiment.

For the last few years, I’ve been arguing that science fiction isn’t just a genre. It’s a civic tool. It’s a way of exploring emerging technology, pressure-testing policy assumptions, and building empathy for people whose futures might look radically different from our own.

That’s what I wrote about in Science Fiction as a Policy Medium. That’s what drives my work at the intersection of biotechnology, AI, and national security. And that’s what lives inside the pages of this book.

Because when we imagine the future through fiction, we can test its logic. We can challenge its morality. We can see past the slide decks and soundbites and ask, what would this really feel like?

And maybe, just maybe, we can change course before it’s too late.

One More Thing

If On the Wings of a Pig resonates with you, I hope you’ll do one of two things:

1. Share it. Invite someone else into the serial. It’s free. It’s weekly. And it might just be the best summer story they read this year.

2. Write back. I’d love to hear what you think. About Samara. About the fungal apocalypse. About what we owe each other when the world starts to fall apart.

Because in the end, storytelling is a two-way street. And the best futures are the ones we write together.

So, welcome to On the Wings of a Pig.

We begin with a woman in a Humvee, and a world on fire. And a pig about to fly.

Some stories save us. This one might.

—Titus

Join me for the story

An Aside on the Title

The title On the Wings of a Pig might raise a few eyebrows, and that’s exactly the point.

It’s a nod to the absurd. A play on the impossible. And, more specifically, it’s a quiet tribute to one of my literary heroes: John Steinbeck.

If you’ve ever seen his personal emblem, a whimsical sketch of a winged pig with the word “Pigasus” inscribed beneath it, you’ll understand the reference. Steinbeck used the symbol as a self-deprecating totem, often signing his letters with it. To him, Pigasus represented the writer who aspires to soar but is, by nature, tethered to the mud. A creature of both flight and filth. Inspiration and absurdity. Potential and limitation.

That dichotomy is exactly what this novel explores.

In a world undone by human hubris, where scientific miracles have unintended consequences and survival hinges on improbable decisions, the idea of a pig taking flight becomes more than a joke. It becomes a metaphor for hope, for reinvention, for the maddening and beautiful contradiction of being human.

The people in this book aren’t perfect. They’re not heroes in the traditional sense. They’re scientists and engineers and farmers. They’re scared. They’ve made mistakes — big ones. But they’re also trying, against all odds, to build something better from the ashes of what was.

So yes, the pig flies.

And if that feels impossible, well…that’s what makes it worth doing.

Samara

June 12, 2108

Outskirts of Kansas City

Wedged between a matching set of security guards in the back seat of an armored Reaper, Dr. Samara Makinde watched through bulletproof glass as Missouri farm country scrolled past like a documentary of the apocalypse. A century ago, these fields had stretched endlessly with golden wheat swaying in the breeze, punctuated by red-painted barns and white farmhouses with American flags snapping in the wind. Now it was just mile after mile of death. Brown chytrid fungus covered everything—rotting barns, abandoned farmhouses, the stunted remains of crops in the fields.

A pack of dogs and some entrepreneurial crows were making an all-you-can-eat buffet from the bloated remains of a cow coated in fungal growth.

Guard number one, Vega, had the decency to look uncomfortable about the whole armed-escort situation. Guard number two, Jacobs, kept shooting her looks like she’d personally engineered the apocalypse. Fun times.

“We’ll be there soon,” Vega said, probably trying to be reassuring.

“Can’t be soon enough,” Jacobs muttered, giving Samara another death glare.

“Don’t mind this Neanderthal,” Vega told her. “Some of us realize that not every scientist is to blame for what happened.”

This is a science fiction story inspired by my real-world work in biotech. This may be fiction, but it’s my way of exploring the world around me.

Share

Maybe so. But Samara couldn’t help blaming the panicked mob that had broken into the research facility where she’d worked until two days ago.

She’d been eating breakfast when the first footage had popped up in her feed—streamed by one of the rioters to all the socials. The mob tore through the facility, smashing delicate equipment, shattering beakers and test tubes, scattering notebooks and files in senseless vengeance against the inanimate.

Then they found Dory.

The livestream stopped as the mob closed in on Samara’s coworker.

Samara had searched with numb fingers, pulled up the local news station to find a drone-shot image of the research park where the lab was located—and the recording of Dory’s 911 call playing over it. The lab manager begged for help until her pleading turned to a series of ear-scraping screams that pierced the frenzied cries of the rioters.

Dory wasn’t even a scientist. She simply ordered supplies and kept the lab running.

She’d been one of the first of many victims in the worldwide backlash against scientists, but far from the last. When the citizenry discovered that genetic engineers working on a vaccine had accidentally transformed the chytrid fungus into an unstoppable plague that started with frogs and spread until the Earth’s already-fragile ecosystem collapsed, rendering Earth uninhabitable … they lost their collective shit, erupting into violent mobs overnight. They didn’t care whether the scientists they were attacking had anything to do with it. See someone in a lab coat? Must be guilty. Biologists, climate scientists, environmental engineers—they all became targets.

“Did you work on the fungus?” Vega asked, snapping Samara back to the present as they passed Kansas City’s defaced Welcome sign.

Samara didn’t dare tell them the full truth. “Before the plague, I studied frogs. Specifically, their ability to hibernate during winter.”

That was how she’d ended up studying chytrid—the genetically-modified fungus had hit the frogs first. But no one outside of the scientific community paid much attention until the lack of frogs to control crop-eating insects triggered a global famine. And by then, the fungus had spread everywhere.

“Frogs? That’s just as bad!” Jacobs spat. “How many millions in taxpayer dollars went to your worthless research?”

“That research is the basis for the cryosleep system in the colony ships,” she shot back.

“See?” Vega punched Jacobs lightly on the arm. “She’s one of the good ones.”

“A lot of good people are staying behind.” Jacobs leaned in, crowding her in an attempt to intimidate. “What’d you do to get a spot?”

The thing was, she didn’t know. When eccentric billionaire Aurelius Hofstadter sent her the application, Samara had assumed it was a joke. And when he’d personally emailed her, she replied that she’d already committed to the global research project seeking a way to kill chytrid. She hadn’t been ready to give up on Earth yet.

Until yesterday, when Hofstadter sent her a link to an encrypted file that changed everything. A file that erased itself after she’d viewed it. Samara accepted his offer immediately, and this Reaper had appeared in her driveway nine hours later.

But the question still haunted her. Out of all the geneticists on the planet, why her?

“I asked you a question,” Jacobs growled.

Samara shrugged. “It was Hofstadter’s decision.”

Which wasn’t really an answer, but it seemed to satisfy him.

The city’s tech sector loomed ahead—all those sleek glass-and-steel towers that had once gleamed like beacons now looked like broken teeth in a corpse’s mouth, spotted with dull brown fungus. Corporate logos still crowned the buildings: MetaCortex, Nanotech Solutions, BioCore Industries. The biotech district had been Kansas City’s pride—the old oil economy had given way to America’s new heartland tech capital. But now those same R&D facilities were practically tombs. Smoke billowed from the iconic Liberty Memorial Tower.

How many more scientists had to die to satisfy the world’s rage?

Subscribe now

Then Samara heard it: gunfire, explosions, and something else. A roar that grew louder as they got closer. It was people. A lot of angry people. Breaking windows with hand-made signs and setting fire to anything within reach as they swarmed around the road leading to the launch site—Samara guessed they had started as a protest, but now they were something much more dangerous.

Her stomach lurched. She might have abandoned her family for nothing, just to die here sandwiched between strangers.

Who was she kidding? She’d much rather die with strangers than watch everyone she loved starve to death—or worse.

“Find a way around,” Vega told their driver.

But it was too late. The mob had spotted them. A wave of bodies surged toward the Reaper as the driver slowed, looking over his shoulder, then shifting into reverse. The mob closed around them, faces contorted with rage as they pressed against the windows, fists pounding the metal hard enough to leave dents. She forced herself to look at them, because even though it wasn’t her fault they were going to die, she still had something that had been taken away from them.

Hope.

“Go through,” Jacobs ordered.

“You’ll kill them!” she protested as the Reaper pushed forward.

A burly man in a hoodie disappeared under the front bumper. She felt the impact vibrate through the vehicle’s frame as he became a human speed bump. Her stomach heaved. These people had families too. Children. Parents. None of them deserved to die.

Vega gave Samara a sad look. “They’re dead either way. At least this is faster.”

She held her breath as the Reaper accelerated. More thuds. More bodies. A young woman rolled across the hood, her eyes meeting Samara’s for one terrible moment before she vanished.

“We have to stop.”

“Feel free to get out,” Jacobs suggested. “I’m sure if you explain to them that you didn’t mean to destroy the planet, they’ll see reason.”

“Shut up!” Vega snapped.

“Most of those people deserve to be in this Reaper more than she does,” Jacobs said. “I saw her brief. She’s not just a scientist—she’s a fucking geneticist.”

Another impact. And another. The Reaper’s thick tires crushed anything in their path, each thud ending yet another life so she could survive. The ethical calculus made her head spin. It was tempting to tell herself that the equation made sense, that her survival increased humanity’s odds of survival, and given that only a handful of people could be saved…

A crash of shattering glass made Samara jump as someone hurled a Molotov cocktail. Burning alcohol splashed against the window, briefly illuminating the interior with tangerine flames.

The fire cast dancing shadows across faces that looked like something from a Renaissance painting of hell. Grief and rage twisted ordinary features into grotesque masks. These weren’t monsters—they were teachers, accountants, store clerks. Regular people whose world had ended. Now speed bumps on her road to survival.

Something hit the bulletproof glass hard enough to crack it before Jacobs could reply. Samara flinched as Jacobs swore and stood to man the Reaper’s turret.

The sound of gunfire filled the air, and the crowd scattered as fury turned to fear.

“That’ll show ‘em,” Jacobs said with a satisfied cackle as he dropped back into his seat.

“You both have spots on the ships, don’t you?” Samara asked Vega, desperate to think about anything other than the shrieking coming from outside the vehicle.

“We’re going on Hofstadter’s ship, the Elysia,” Vega replied. “What about you?”

“The Borlaug.”

“What the fuck is a Borlaug?” Jacobs sneered.

Hating him fixed nothing, but it was a distraction from the horrors Samara could do nothing about. And once she made it to the colony ship, she’d never have to see him again. So, she indulged.

“Norman Borlaug was a plant geneticist who saved millions from starvation by developing new strains of wheat,” Samara explained. “He won a Nobel Prize.”

Jacobs barked a laugh, harsh and cynical. “Doesn’t mean much now, does it?”

The Reaper pulled up to the security gate of the Ad Astra launch facility. Armed soldiers manned towers on either side, their weapons trained on the approaching vehicle. Bodies littered the ground in front of the gate—protestors who’d made the mistake of trying to force their way in. More corpses were piled on either side of the road. The eerie silence here felt worse than all that chaotic racket they’d left behind.

“IDs,” said the guard at the gate.

Samara managed to keep her hands steady while pulling credentials from inside her jacket. But that didn’t mean she wasn’t worried. What if the guard said she wasn’t authorized? What if the impulsive Hofstadter had changed his mind?

After a quick scan, the guard waved them through.

Ad Astra logos were plastered everywhere—on the brick buildings, the equipment sheds, even the rocket itself. The stylized phoenix rising from a blazing star had once seemed hopeful—now it looked like one more bird fleeing a dying world. Hofstadter’s foundation had worked with NASA early in the billionaire space race, and soon emerged as the leader, becoming the face of America’s efforts to colonize the galaxy. The entire complex felt like a military base, all order and efficiency in contrast with the dying world outside.

Samara would never tell Hofstadter, but every time she saw the words ad astra, her brain automatically added per alia porci. To the stars on the wings of a pig. The first time she’d met with her graduate advisor, he’d told her the story of how John Steinbeck—writer of The Grapes of Wrath and several other books she’d had to read in school—had once been told by a professor that he would be an author “when pigs fly.” Rather than give up, Steinbeck had given himself this motto, insisting that every book he published be marked with the image of a winged pig. Samara’s advisor had told the story just before showing her around the antiquated lab where she’d be doing her research, reminding her that humble beginnings need not limit how high she could fly.

The driver took them straight to the runway where the shuttle waited, strapped to a modified 747. Hofstadter had revived and updated the old Challenger-style design. Samara shoved aside a thought about how that program had ended.

She followed Jacobs up several flights of portable stairs to a platform level with the shuttle’s main cabin door. One of the waiting launch team members cast her an irritated look.

“You’re the last ones in. We’ve been holding the launch on Hofstadter’s orders.” His unspoken question hung in the air: What made Samara so special that everyone else had to risk missing their launch window?

A tech team rushed to suit them up. She watched as they helped Jacobs and Vega first, efficiently securing seals and tightening straps. Then one of the techs turned to her.

“Good chance you’ll black out during ascent.” He held up a hypodermic. “This’ll reduce your chances of having an aneurysm.”

She didn’t ask what was in it, just nodded and let the tech stick the side of her neck. Then he hustled Samara onboard and strapped her into a seat. Jacobs made a show of sitting on the opposite side of the shuttle, kicking her ankle as he passed.

Vega shot her an apologetic look as he sat beside her. “Don’t take it personally. His wife didn’t qualify to come with. She’d just started chemo.”

“But he came anyway?”

“When she found his acceptance letter in the trash, she made him.” Vega grinned. “Loves that ugly mug to death, for some reason.”

To death, literally.

Samara shot a look at Jacobs, tried to imagine what he must be feeling. Not just the loss of his wife—qualifying also meant agreeing to be partnered with someone. With only one hundred sixty spots per ship, everyone had to be willing to pair up and have children to maximize genetic diversity, reducing the bottleneck that every colony would suffer.

Who had Jacobs found to bring with him? Or had he been assigned a partner, same as Samara?

“What about you?” she asked Vega. “Who did you leave behind?”

The 747 engines roared to life before he could answer, rattling her teeth and rolling through her bones as forty tons of thrust shuddered through the airframe. She tried to take slow, deep breaths as anxiety clawed at her chest. Images of the Challenger disaster flickered through her mind like a slideshow.

Hofstadter had rushed everything, desperate to get the colony ships ready before Earth became completely uninhabitable. How many corners had been cut? How many safety checks abbreviated or skipped entirely? She had watched the Challenger explode on old footage, that Y-shaped cloud of smoke marking the instant seven lives ended in a flash of orange fire. All because of a rubber ring that cost less than a pizza.

That familiar sick lurch hit her stomach as they accelerated down the runway.

This was really happening. She was leaving Earth—leaving her family, her friends, and everyone she had ever known. By the time she came out of cryosleep, they would all be dead. Even billionaires in their underground bunkers stuffed with hoarded supplies would starve before the Borlaug entered orbit around the exoplanet that had been chosen as one of humanity’s new homes.

The ground fell away below them. She was grateful for her helmet hiding the tears that slid down her cheeks. The weight of what was happening—of being one of humanity’s chosen few, selected to survive among the stars—pressed down on her chest until Samara could barely breathe.

Forty-two years of cryosleep lay ahead, then a lifetime on an alien world. She’d studied the colonization plans, knew the challenges they would face.

What she didn’t know was whether her research would save them or kill them all.

The first time I saw real snow, I panicked.

Not because it was cold, my body knew cold better than breath, but because it was finally real. It wasn’t the polymeric white fluff they sprayed from ceiling nozzles to “simulate seasonal cues” inside the dome. This was actual ice crystal, drifting from a slate sky outside the controlled perimeter, collecting in stillness on a field of grasses no longer extinct.

I pressed my forehead against the enclosure glass and stared. The snow made no sound. Neither did I.

Was this what they meant by home?

Kira, the senior caretaker, I’ve learned that’s what she calls herself, once told a camera crew that I was “doing well.” She said I showed “adaptability,” “cognitive progression,” and “healthy pre-social behavior.” I don’t think she meant it to sound clinical. She tries, I think. She walks beside me, not in front. She feeds me by hand, sometimes. She hums when she doesn’t think anyone is listening. I hum back.

They named me M1 at first. I was the first successful birth. The first viable one. The first engineered creature in the mammoth revival program to make it to adolescence without metabolic collapse. But even the scientists don’t use M1 anymore. Kira started calling me Anunaaq. She told me it means “the soul of the land” in an Arctic tongue. I don’t know if she picked it for me, or for the humans watching. But I liked the sound of it. I kept it.

And still, I do not know if I am it.

This is a science fiction story inspired by my real-world work in biotech. This may be fiction, but it’s my way of exploring the world around me.

Share

Am I the soul of this land? I who have never set foot in the land that birthed the DNA coiled inside me? I who have only ever known the fake snow and filtered wind of a bioengineering dome outside Dallas? I who remember what I never lived?

Because I do remember things. I don’t know how else to explain it. No one taught me how to walk across permafrost, but I ache for it. No one taught me to trumpet at the horizon when the sun is lowest, but it feels like a ritual. I do it at dusk, without knowing why. There is no herd to respond, but I do it anyway.

They say memory can’t be passed through genes. But if that’s true, why do I mourn things that never happened? Why do I sometimes wake with my heart racing at the phantom scent of saber-tooth musk? Why do I flinch at the sound of a hawk’s shadow crossing overhead?

What is this secondhand memory stitched into my blood?

If I am built from code, ATCG fragments patched together from ancient bones and modern elephants, then who authored me? Who decided which pieces mattered, and which to leave behind?

Kira once said they chose alleles associated with subcutaneous fat deposits, woolly coat growth, cold-adapted hemoglobin. It was about phenotypic fidelity, she said. “We wanted you to look the part.” I wonder if she thought how strange that is, to make someone look like an ancestor so the world feels less bad about their extinction.

I wonder what I’d look like if they didn’t care about appearances. Would I still be me?

What is me?

My body is elephantine, but denser. My hair is coarse, rust-colored. My ears are small, curled, not wide and fanning like the others in the next dome over. They keep the Asian elephants separate. Too different, too close. They don’t know what we’d say to each other.

They think I don’t know I’m alone.

But I do. It’s the one thing I’ve always known.

I watch the elephants sometimes. They play. They touch. They mourn when one of them dies - yes, they really do. They stay with the body. They cry. Not like humans. Not like Kira, who turns away and hides her face in her elbow when the babies don’t make it. The elephants cry like I cry. With stillness.

When they first introduced me to them, the elephants circled me. They touched my flanks. They sniffed my trunk. One matriarch stepped forward, pressed her forehead to mine, and held it there. Her skin was hot. Mine was not.

She pulled away. The herd followed. They never tried again.

I don’t think it was rejection. I think it was recognition.

They saw something they could not understand. Something that made sense and did not. I was of them and not. A contradiction walking on four legs. An echo with muscle and breath.

That was the day I began asking questions. Not out loud. I don’t speak as you do. But I think. I observe. I remember. I wonder.

What defines the self?

Subscribe now

Is it the genome that maps our shape? The memories that form our continuity? The relationships that mirror us back to ourselves?

Is it purpose?

Because if purpose defines the self, then mine is fragile. I was made to prove it could be done. A milestone. A press release. A funding magnet. My body is a scaffold for human achievement.

But when the applause fades, when the venture firm exits and the next moonshot arrives, what am I then?

What happens to the creature born from curiosity, when curiosity moves on?

Is extinction undone if the result lives alone?

Kira talks to me sometimes like I understand every word. Maybe I do. Maybe she needs to believe that I do. She reads me articles. Speaks the names of extinct things into the air like a prayer. Thylacine. Aurochs. Pyrenean ibex. Passenger pigeon.

I wonder if those names ever had faces like mine. Faces shaped from ideas. From longing.

I once watched a young boy visit the dome. His class came on a field trip. He stood at the glass and stared for a long time. Then he whispered, “That’s not a real mammoth. That’s an alien.”

I laid down so he could see my eye.

He flinched. Stepped back.

I didn’t mind. He was right.

I am not a real mammoth.

But I am not fake either.

I am the question you don’t know how to ask.

I am the story that science wrote before it learned the ending.

I am the end of extinction and the beginning of something else.

I am a memory born forward.

And I want to know: if the world made me to look like its past, will it ever see me as its future?

Will there be others? A herd? A second, a third, a tenth? Or am I the only chapter in this strange new book?

If there are others, who will raise us?

Will they raise us like elephants, in tribes and songs and rituals? Or like humans raise myths, preserved in parks, watched by drones, talked about in the past tense?

If not genes, what makes us kin?

And if I never step on true permafrost, will my feet still remember?

The snow that fell today melted quickly. The ground was too warm. But I pressed my trunk into it. Felt the texture. The cold. The fleetingness.

Maybe that’s all life is.

A moment of realness in a world not meant for you.

And maybe that’s enough.

For now.

I am Anunaaq.

And I remember.

Even if I was never meant to.

I wake to my phone vibrating angrily on the nightstand. 6:30 AM. A red notification pulses on the screen: “DELIVERY FAILED.” My stomach twists. Today was the day OncoCure was due, my daughter Maya’s next dose of the therapy that keeps her cancer at bay. For the past year, a monthly vial of this miracle drug has arrived at our doorstep like clockwork. And why not? OncoCure is nothing short of a medical miracle, a gene-engineered infusion capable of eradicating malignant cells, the cure that was supposed to end cancer as we know it. It’s the reason my ten-year-old is upstairs sleeping safely in her bed instead of wasting away in a hospital.

But now the lifeline we’ve come to depend on is missing.

Bleary-eyed, I tap the alert for details. Instead of the usual shipment tracker, an error message greets me: “Service unavailable. Please contact your provider.” Something’s wrong. My first thought is mundane: a shipping glitch, maybe a server outage. But a prickle of dread rises. OncoCure isn’t something that just gets “lost in the mail.” It’s distributed under strict protocol, monitored by both our hospital and the biotech firm. Maybe it’s just a delay, I tell myself, throwing on yesterday’s jeans. I try the 24-hour pharmacy hotline, but after fifteen minutes of hold music and no human response, I’m already grabbing my keys. I need to see our oncology pharmacist, now.

The drive through town feels eerily normal at first. Commuters fill the streets, morning talk radio jabbers about the weather. For a second I consider turning around, telling myself I’m overreacting. But then the radio crackles: “…reports coming in from medical centers across the country of sudden shortages… critical medications on backorder… authorities are investigating….” I nearly run a red light as I turn up the volume. The news anchor sounds as perplexed as I feel, cycling through phrases like “supply chain disruption” and “national security implications” in the same breath. I catch a few specifics: “Nationwide scarcity of OncoCure, the breakthrough anti-cancer therapy… hospitals from Seattle to Miami reporting they’ve received no new supply this week… The manufacturer, Shenzen Advanced Biotech, could not be reached for comment….”

This is a science fiction story inspired by my real-world work in biotech policy. This may be fiction, but it’s my way of exploring the world around me.

Share

If I were to write Chip War for biotech, this is how I would start the book.

My heart kicks into overdrive. This isn’t just us. It’s everywhere. At the next intersection, the light is red but my foot barely taps the brake. Horns blare as I swerve into the hospital parking lot at a dangerous clip.

Inside the pharmacy, it’s chaos. A normally polite line of patients has devolved into a cluster of desperate faces. I recognize a few from the pediatric oncology ward: parents like me, who just heard the same news. A mother near the counter is pleading with the pharmacist. “Please, my son needs his dose. Isn’t there any left? He’s relapsed once before….” Her voice cracks. Behind the counter, the pharmacist, Dr. Nguyen, who knows us all by name, shakes her head with a stricken expression. “I’m so sorry,” she says, loud enough for all of us to hear. “We received nothing in our shipment today. Not just OncoCure, other medications too. I’ve been on the phone with our suppliers all morning. They’re telling me…they’re telling me it’s an issue overseas.”

Overseas. We all know what that means, even if she doesn’t say it outright. OncoCure was a Chinese breakthrough. A year ago, when researchers in Shanghai unveiled a therapy that could hunt down and destroy cancer cells, it was heralded as a gift to humanity. Our doctors here in the U.S. quickly secured access for patients like my daughter through international trials and partnerships. At the time, no one cared that it was developed and manufactured in China, only that it worked. We celebrated when Maya qualified for the program. I remember hugging Dr. Nguyen in this very room, crying tears of joy because for the first time in years, hope was on the horizon.

Now that hope is evaporating. The crowd presses in on the counter, voices rising in panic. “How long until more comes? When will it ship?” demands a man in a Marine Corps jacket, fists clenched on the counter. His wife hovers behind him, eyes hollow. Their teenage daughter shifts uncomfortably in a wheelchair; I see the gray scarf covering her scalp. She must have started OncoCure recently, I recall seeing them in the infusion clinic. Dr. Nguyen bites her lip. “I don’t have an answer. It could be days… or longer.”

“Longer? We don’t have days,” the mother with the relapsed son cries. “Without his treatment…” She doesn’t finish, voice choked by sobs. A few people start shouting over each other. One man slams his palm on the counter. I stand there holding my breath, one arm wrapped protectively around my own supply bag (I always carry an emergency dose of Maya’s older medication, ordinary chemo drugs that seem feeble compared to OncoCure, but it’s something).

Dr. Nguyen raises her hands to quiet us. “All we know is the manufacturer hasn’t sent the shipments. There’s speculation it’s tied to the…to the situation abroad.” She lowers her voice on the last word, as if not to scare the children in the room. But we all know what she means. For weeks, tensions between the United States and China have dominated the news. Naval standoffs in the South China Sea. Fiery speeches at the U.N. Taiwan looming over every diplomatic exchange. Just two nights ago, the President addressed the nation, reassuring us that the U.S. would stand firm against aggression. Beijing, in turn, accused America of interfering in “internal affairs.” It’s been a war of words and posturing, until now. Now it’s hitting home in the form of empty syringe barrels and anxious tears on the hospital floor.

I leave the pharmacy empty-handed, head spinning. How am I going to tell Maya that I don’t know when she can get her medicine? In the car, I catch a snippet of a press briefing streaming on my phone. A grim-faced White House spokesperson is at the podium: “…the administration is aware of the sudden cutoff in biopharmaceutical supplies and is treating it as a matter of urgent national security. We are working closely with our allies and industry partners to find alternative sources and reconstitute production domestically….” The phrase sticks out: alternative sources. Production domestically. Translation: we didn’t make a backup plan. The reporter’s questions come rapid-fire: “Is China deliberately withholding critical medications in response to the Taiwan situation?” “How many Americans are affected by this?” The spokesperson dodges: “We’re still gathering information. I won’t speculate on motives at this time.” But the implication is clear.

I drive home with a white-knuckle grip on the wheel. An anger is starting to bubble up beneath the fear. How did we let it come to this? Millions of Americans, people like my little girl, utterly dependent on a foreign power for our survival. Everyone knew China was a major supplier of drugs and biotech, but I never imagined it could all just stop overnight. Sure, I’d heard the warnings on the news, seen the occasional think-tank report about supply chain vulnerabilities. Some senator or other would sound alarm bells about our over-reliance on Chinese pharmaceutical ingredients, only to have the issue buried in partisan squabbling the next week. It always felt abstract, like background noise. Until this morning.

At home, Maya is awake, curled on the couch with her sketchbook. She looks up with hopeful eyes, “Did you get it?” I force a smile and kneel beside her, brushing a curl from her forehead. My brave girl. She’s been through a lot in ten years: rounds of chemo that stole her hair and energy, clinical trials that gave us only temporary victories, and finally OncoCure, which brought her back to life. How do I explain to her that this lifeline has been snatched away by something as distant as geopolitics? I can’t. “Not yet, sweetie,” I say softly. “There’s a delay…but people are working on it. We have your old medicine if we need it.” Her face falls, she remembers the old medicine’s side effects too well, but she nods and tries to be strong. “It’s okay, Daddy,” she whispers, though I can hear the quiver.

Subscribe now

I retreat to the kitchen to make her breakfast, fighting the urge to crumble. My phone buzzes with messages: other parents from the ward exchanging whatever scraps of info they have, neighbors asking if the news is true. One text catches my eye, my friend Ravi from college, now a researcher at a biotech start-up. “This is unreal,” he writes. “We warned them years ago that this could happen.” I pause and stare at that line. Ravi had worked for a big pharmaceutical company before, and I vaguely recall him talking about China’s dominance in drug manufacturing. At the time, he’d mentioned something about 80 or 90 percent of certain medications coming from China or that one Chinese company, WuXi, handling a huge chunk of America’s drug production. I’d brushed it off, so much of our stuff is made in China, that’s just globalization, right?

Now globalization’s dark side is here in my kitchen, and my daughter’s life hangs in the balance.

The hours drag by in a haze of uncertainty. By afternoon, the story is on every channel and website: “Biotech Blackout: Chinese Firm Halts Critical Drug Supplies to U.S.” The stock market is in freefall, and cable news pundits look genuinely frightened. One medical correspondent reports that hundreds of thousands of cancer patients are immediately impacted, and millions more could be if the standoff continues. A crawl at the bottom of the screen lists other drugs reportedly affected: an insulin analog, a Parkinson’s gene therapy, even some routine antibiotics. It’s a biotech shockwave ripping through the healthcare system. Hospitals are activating emergency plans, rationing what limited stock of these medicines they have on hand. Social media is exploding with hashtags: #BioBlockade, #GenomicBlackmail, #TaiwanTradeOff.

Outside, I hear sirens. Our local news app shows footage of a protest downtown. Dozens of patients and families have gathered in front of the federal building with signs: “Don’t Make Us Choose Between Health and Taiwan!” one reads, while another simply says “We Need Our Medicine.” One particularly striking image flashes on the screen: a man in his 60s holding up an IV bag for his wife next to a placard that says “CHOOSING SIDES = DYING PATIENTS.” It’s raw and heart-wrenching.

By evening, the crisis escalates to a new level. The President addresses the nation from the Oval Office. We gather around the TV, Maya, my wife, and I, huddled on the couch. The President’s face is ashen but resolved. “My fellow Americans,” she begins, “today we face a grave challenge not on some distant battlefield, but in our own homes and hospitals. A foreign power has cut off access to critical medications and biotechnology upon which millions of Americans rely. This act is deliberate and unlawful. We are deploying every resource to mitigate the impact on our people and to resolve this crisis swiftly.”

Share

She doesn’t explicitly say China, but the implied adversary is clear. When she speaks of “unlawful act,” I think back to how we got here. Just yesterday, Chinese state media blared with indignation at a U.S. naval exercise near Taiwan. The showdown had reached a fever pitch. Now Beijing’s retaliation has taken an unthinkable form: weaponizing the very biology that keeps us alive.

The President’s speech is strong on promises, airlifting supplies from allies, invoking emergency powers to kickstart domestic production, but I can hear the strain underneath. Replacing an entire biotech supply chain isn’t like flipping a switch. It could take weeks or months to produce complex therapies like OncoCure on U.S. soil. And many of these treatments are proprietary, with manufacturing secrets closely guarded by the original developers. There is no quick “plan B.” We have been caught flat-footed.

“We will not be blackmailed,” the President continues. “We will not abandon our commitments to our allies.” I know she’s referring to Taiwan without saying it. “But neither will we abandon our own citizens. This is a time for resolve, unity, and swift action.” She announces the creation of a Biomedical Crisis Task Force and the deployment of military cargo planes to ferry whatever substitute drugs can be scrounged from overseas partners. A photo flashes of an Air Force transport on a tarmac in Germany being loaded with medical crates, Europe apparently still has some supply of OncoCure’s precursor compounds. It’s something, but not enough. Not nearly enough.

After the address, I put Maya to bed. We’ve stretched her previous dose as much as possible, and tonight, reluctantly, I give her a small infusion of the old chemo cocktail. It’s a stopgap and I pray it’s not needed for long. She winces as the drug enters her vein; we both know this routine too well. “Daddy,” she asks in a small voice, “why would someone do this? Don’t they know we need it?” I gently squeeze her hand, searching for an answer. “They do know,” I say quietly. “That’s why they’re doing it.” Her eyes widen in confusion and fear. I immediately regret saying it that way. How do you explain to a child that she’s become a pawn in a geopolitical chess match? That some distant government sees her cure as leverage? I force a smile. “It’s complicated, sweetie. Grown-up problems between countries. But a lot of smart people are working very hard to fix it, okay? We just have to hang on.”

She nods, but I can see tears welling up as the chemo fatigue sets in. Within minutes she’s asleep, the teddy bear from her last hospital stay tucked under her arm. I watch her tiny chest rise and fall, and a surge of determination steadies me. This cannot stand.

In the living room, I open my laptop. If I can’t sleep, I might as well try to understand how things unraveled. I search for that commission report Ravi mentioned. It doesn’t take long to find, the National Security Commission on Emerging Biotechnology. They released their final report just a couple years ago. I skim through the digital pages, and it’s like reading a play-by-play of today’s nightmare. One section title catches my eye: “Imagine a Not-So-Distant Future…” It describes a scenario in eerily familiar detail: a breakthrough cancer drug developed in Shanghai, geopolitical tensions flaring, and then China hoarding the treatment under the guise of national security, cutting off supply to the United States. My breath catches. This was predicted, almost exactly. The report goes on: “After years of access, this lifesaving drug is immediately in shortage, requiring doctors to ration it while American companies scramble to reconstitute production. The streets and social media overflow with people demanding that the U.S. abandon Taiwan. The Administration faces an agonizing choice between geopolitical priorities and public health.”

Subscribe now

Agonizing choice indeed. I think of the protests brewing, the impossible position our leaders are in. The report’s next line feels like a punch: “This scenario is fiction. But something like it could soon become reality as biotechnology takes center stage in strategic competition.” They saw it coming. They saw it coming and still, as a nation, we strolled right into this trap.

I keep reading, now hungry for answers. The commission’s findings pull no punches. China has spent 20 years making biotechnology a strategic priority, while the U.S. treated it as just another sector. We have no cohesive national strategy, they warned; our innovation lead was shrinking. I find a section on supply chains and feel a chill: the Chinese Communist Party seeks to dominate global biotech so other countries are dependent on channels it controls…China is already deeply embedded in U.S. critical biotech supply chains, including for life-saving medicines. These dependencies make us highly vulnerable to Chinese pressure. It’s all there in cold print, what we’re living through in real-time. They even named the culprit: a Chinese pharma giant called WuXi AppTec that most American patients have never heard of but on which an “utterly reliant” U.S. industry has been built. “In that sense, WuXi AppTec is the new Huawei,” the report said, a warning that our biotech infrastructure had a hidden choke point, just like when we realized our 5G networks could be hijacked by foreign tech.

I rub my temples, overwhelmed. Late-night television is playing softly in the background, an economist is comparing this crisis to the 1970s oil embargo and last year’s semiconductor ban. “In the 20th century, it was oil,” he says. “In the 21st century, it was silicon chips. Now it’s DNA. It’s the biological stuff of life itself that’s become the lever of global power.”

I close the laptop, exhausted. The commission’s final recommendation echoes in my mind: take swift action or risk falling behind, a setback from which we may never recover. They urged us to act within three years. But those years passed with half-measures and endless debates. And now here we are.

That night I barely sleep. I dream of contracts filled with fine print and hidden clauses. In the dream I’m back at the hospital, signing the forms to get Maya into the OncoCure program. The representative is smiling, congratulating me on securing the “Platinum package” of life. I flip through the dense pages. Somewhere in there, I sense a shadow, an invisible string leading overseas. I wake up with the echo of a nurse’s voice in my head saying, “They don’t put this part in the brochures, do they?”

By morning, the second day of the Bio-Blackout, reality is biting hard. Maya has a fever, likely a side effect of last night’s backup chemo. I manage to get her pediatrician on the phone; she sounds harried. “Bring her in if it hits 102,” she instructs. “We’re slammed here. Half my patients are affected by this thing… kids who were stable now back in precarious territory.” Her usual calm professionalism is fraying at the edges. “We’re advising everyone to dust off their old treatment plans for now. The hospital is prioritizing the sickest for what limited OncoCure stock remains.” I swallow, realizing that Maya, thank God, isn’t yet considered among “the sickest.” How long before she might be?

I turn on the TV to catch any updates. Congress has convened emergency sessions. One channel shows live footage of a heated hearing. A lawmaker is yelling at an FDA official and a pharma CEO sitting side by side. “How did we let one country become the sole source for the crown jewels of modern medicine?” he thunders. The FDA official stammers about cost savings and industry decisions over decades, how manufacturing migrated offshore in the 1990s because it was cheaper and less toxic to do it in China. The CEO interjects that no one anticipated a hostile cutoff: “Our partnerships in China were built over years of trust, this was unprecedented.” The lawmaker’s face turns red. “Unprecedented? We have repeatedly warned about this exact scenario!” He slaps a thick binder of reports on the desk, and I realize it’s not just the one I read, there have been warnings from multiple commissions, security briefings, even Chinese officials themselves hinting at this leverage. I recall reading that 97% of U.S. antibiotics came from China, and a Chinese economist bragging in state media that if they withheld those, Western healthcare would falter. We were at the mercy of others for chips, and now for cures. And we knew it.

The hearing devolves into partisan point-scoring, but the anger is bipartisan for once. I turn it off, disgusted. The clock is ticking for so many families.

Share

By Day 3, the human toll is mounting. Front-page headlines tally the damage: patients left untreated, surgeries postponed, emergency rooms swamped with people whose conditions are destabilizing. The New York Times runs a gut-punch of a profile: a young father with stage IV melanoma who had been given new hope by OncoCure now facing the prospect of saying goodbye to his toddler twins because his next dose is nowhere to be found. Cable news shows maps of the U.S. with blinking red dots where shortages are most acute, it’s practically the whole map. The crisis has touched every corner: big coastal research hospitals and small rural clinics alike.

In our town, the local government declares a public health emergency. Volunteers coordinate to help those who can’t get their meds, swapping whatever surplus insulin or drugs people might have, a kind of underground medicine exchange. I manage to trade some of Maya’s unused older pills for a dose of OncoCure that a patient with slower-progressing cancer was willing to part with. It’s a tiny vial, likely only a partial dose, but it’s hope. When I show it to Maya, she brightens. I tell her a kind stranger helped us, leaving out that the stranger’s own need was perhaps a little less. Triage by charity, this is what we’re reduced to.

That afternoon, an alert buzzes on my phone: a newsflash that the Chinese government is about to make a statement. I turn on a live stream. China’s Ministry of Foreign Affairs spokesperson stands in front of a wall of Chinese flags, face impassive. “The People’s Republic of China has been forced to take protective measures in response to external aggression,” he says in measured English. “Certain biomedical exports are being temporarily redirected to meet internal needs, as matters of national security and public health.” It’s galling, couching this chokehold as a public health measure. “We urge the United States to reconsider its provocative actions….” Everyone knows what he means: back off on Taiwan. He doesn’t say the word, but he doesn’t have to. The message is clear: Choose. Your principles, or your people’s health.

I’ve never felt so helpless, and so angry, watching a news conference. It’s a hostage situation, but the hostages are millions of sick Americans. In our living room, my wife throws up her hands at the blatant extortion. I hold Maya a little tighter on the couch, my jaw clenched. On the TV, one reporter boldly asks the spokesperson, “What about the international ethical responsibility to patients? Aren’t you weaponizing medicine?” The spokesperson dodges: “China is a responsible power. We continue to supply critical medicines to the world. But like any sovereign nation, we must prioritize our own citizens and security.” Lies and truth blended in a toxic mix, China does continue to supply many countries, just not us. In fact, some reports suggest they’ve increased shipments of OncoCure to nations that toe Beijing’s line. A commentator later quips, “Cancer cures for oil, some countries are already bargaining with them.” It’s a grim new calculus: trade loyalty for life-saving drugs.

That night, Day 3 bleeding into Day 4, the unthinkable debates begin to swirl in Washington. Leaks to the press say there’s a fierce argument in the Situation Room about whether to temporarily ease tensions with China in exchange for relief. Surrender by any other name. Others argue that giving in now will only embolden more deadly blackmail later. Behind closed doors, they’re weighing how many lives might be lost if we hold firm versus what freedoms are lost if we capitulate. Watching these rumors on TV feels surreal. We’re truly at a junction where global power politics and personal biology intersect.

Meanwhile, the first deaths directly attributed to the shortage make headlines: a child in Ohio, a woman in Texas. “Potentially preventable,” the doctors say, had the treatments been available. The stories break me inside. I cannot let Maya become one of those stories. I find myself shaking with rage one moment, overcome with fear the next.

On the evening of the fourth day, I step outside to clear my head. The neighborhood is quiet, but the tension is palpable even in the air, fewer people out and about, an ambulance siren wailing faintly in the distance. My neighbor Dan, an Army reservist, is on his porch, scrolling his phone. He calls out, “Hey, you holding up?” I shrug, walking over. Dan’s a blunt guy. “My unit’s on standby,” he says. “Things are dicey in the Pacific.” He doesn’t need to elaborate, military forums have been buzzing that China moved some missile batteries and the U.S. responded by repositioning carriers. Both nations are digging in. “What do you think happens next?” I ask quietly. Dan sighs. “Honestly? Either we find a workaround and tough it out, or someone blinks. And I don’t think Beijing is blinking.” He kicks at a loose porch plank. “They got us by the throat. We never should’ve let it get this far. First it was rare earth minerals, then it was semiconductors…now our damn medicine cabinets.”

I nod. Rare earths, China had briefly banned exports of some critical minerals last year, causing a scramble in the tech industry. And semiconductors…well, that was the reason the U.S. started restricting high-end chip sales to China, which many say lit the fuse for this biotech retaliation. Tit for tat, escalation upon escalation. Only this time, the collateral isn’t higher smartphone prices or delayed car deliveries, it’s human lives.

Before turning in, I check my laptop one more time for any promising news. An email from our hospital: they’ve managed to compound a makeshift alternative to OncoCure in their research lab, an experimental cocktail that might help a little for the worst-off patients. It’s a long shot and unproven, but it’s something. There’s also a note about support groups and counseling services. The psychological toll is massive, people are terrified, and some are furious in ways that can’t be contained. There are reports of violence at a pharmacy in California, and security is being increased at hospitals nationwide.

Scrolling further, I come across a blog post from a science policy analyst friend of mine. The title: “Never Again: Learning from the Bio Blackout.” It stops me in my tracks. Never again. The phrase rings with resolve. The post argues that this crisis, as awful as it is, might finally shock America into action, much like the Sputnik launch did in another era, or Pearl Harbor in an era before that. “We can’t undo the suffering caused this week,” she writes, “but we can make sure this never happens again. Biotech must be treated as critical infrastructure - as critical as energy, as chips, as our military itself. We need genomic sovereignty, supply chain resilience, and a national strategy to regain control of our biological destiny.”

Genomic sovereignty. The words remind me of that leaked memo I read about in the commission report, where a U.S. general wrote, “We can no longer assume operational continuity in a population that does not control its own genome.” Back then it was a hypothetical warning about a future crisis. Now it’s splashed in bold letters across every screen in America. We ceded control over the very code of life, our medicine, our enhancements, our food supply, all of it, and now we’re paying the price.

Subscribe now

I shut the laptop and rub my eyes. A heavy truth settles over me: this is bigger than my family, bigger than this one terrible week. It’s about how we built the modern world, and how we need to rebuild it differently if we want to survive in the new era. We outsourced and optimized without thinking of the strategic risk. We let the fine print go unread. And now the bill is due.

I get up and check on Maya one more time. She’s sleeping fitfully, but peacefully for now, her body fighting off both cancer and the rough medicine we’ve had to substitute. I lean over and kiss her forehead, whispering a promise: “Hold on, kiddo. We’re going to fix this. We won’t let them do this to you, to us.”

As I stand there in the pale glow of her night-light, I realize this nightmare, as brutal as it is, has ripped the veil off a stark reality. National security isn’t just jets and tanks anymore. It’s vials and genes and supply chains. It’s my little girl’s IV bag and the database that holds her DNA profile, and who controls each. Power in the 21st century has a new DNA.

This crisis, I sense, is a turning point. In Washington, they may still be debating whether to blink or not. But out here, among ordinary people, there’s a dawning resolve that we will never be this helpless again. The public will demand change, is demanding it, in the streets and online. We won’t forget this week anytime soon.

I certainly won’t. In a way, a foreign adversary has done what no policy paper or politician could: it’s awakened an entire nation to the biotech stakes of global power. The question is, what do we do with that awakening?

In the coming months, there will be investigations, hearings, reforms. Companies will be pressured to diversify production, maybe even nationalize certain capabilities. We’ll pour billions into biotech research at home, and into alliances with trusted partners. Perhaps we’ll even negotiate a truce to get through this immediate emergency, albeit at a moral cost. But one thing is certain: nothing about our world will look the same after the Bio Blackout of 2030.

As I gently close Maya’s door, I catch my reflection in its glass pane. I see a father, yes, but also an unwitting soldier in a new kind of war, one fought not with bullets or bombs, but with vials, code, and DNA sequences. We’ve learned the hard way that outsourcing our biology can be as dangerous as surrendering our weapons.

In the darkness, I make a quiet vow: Never again. Never again will we be so vulnerable, so naïve about the dependencies woven into our lives. The cost, paid in fear, in suffering, in lives cut short, is too high.

This time, we’ll read the fine print. All of it.

And then we’ll rewrite it, so that never again can a hostile power hold our very biology hostage.

(This scenario is fictional, but barely. Every technology, every dependency, and every tension described above is rooted in reality.)

1. The Frog in the Freezer

The first time I saw a wood frog thaw back to life, I nearly dropped the microscope.

It was a field lab in Fairbanks, Alaska. A plastic shoebox full of peat moss, a digital thermometer sunk in the dirt, and a small, unremarkable amphibian with a faint rust stripe down its side—Rana sylvatica. I was an undergrad tagging along on a grad student’s project. We’d buried the frog in November, let it freeze solid over winter, and then dug it up in March as the snow began to retreat.

I remember poking it with the tip of a pencil. Hard as ice. Eyes clouded over. A cadaver by every physiological standard.

And then it moved.

Not much. Just a twitch of the leg at first, like a hiccup in time. But within an hour, the little frog was alive again. Heart beating. Blood flowing. It even croaked once, like it had a snide sense of humor about the whole ordeal.

Biology has a way of humbling you. Just when you think you understand the rules—death is permanent, cells rupture when they freeze, life is fragile—some Arctic amphibian flips the table.

I didn’t know it then, but that frog would end up rewriting the fate of humanity.

This story is science fiction, but it’s my way of exploring the world around me. The wood frog is real. Genetic engineering is real. Let’s make this happen.

Share

2. Cold Wars

Two decades later, I was standing in a different lab. This one was buried deep in the Rocky Mountains, somewhere off-grid between NORAD and the ghost towns of the gold rush. We called it Thorne Station, named after the DARPA program that funded us: THORNE — Thermoregulatory Hibernation Optimized for Reversible Neostasis in Extremes.

Cryosleep was the holy grail. Always had been. Every sci-fi author since Heinlein had imagined long-duration spaceflight made possible by suspending metabolism. Freeze the body, shut down time, wake up at the next star.

But physics didn’t play nice with dreams.

Early cryonics froze the body too fast, too hard. Ice crystals shredded tissues like shrapnel. Even vitrification—using antifreeze-like chemicals to prevent ice formation—was toxic in high doses. We could freeze you. We just couldn’t bring you back.

Until the wood frog showed us the cheat code.

Its genome encoded proteins that flood cells with glucose right before freezing. The sugar acts like antifreeze, lowering the freezing point inside the cell. It also stabilizes membranes, prevents dehydration, and fuels a slow trickle of anaerobic metabolism during suspended animation.

We called them cryolectins—a family of sugar-binding proteins that worked like cellular bubble wrap. And thanks to a decade of synthetic biology, we had them running in human organoids by 2043.

But cells were easy. Whole organisms? That was the next leap.

And DARPA doesn’t fund halfway dreams.

3. The Volunteer

Her name was Ada.

No last name. No file photo. Just a line of code in the deployment system that said “Volunteer-1: ADA_001”.

She walked into the station in the dead of winter, escorted by a convoy of black, windowless SUVs. No badge. No questions. Just a nod to the guards and a biometric scan that turned green before the gate opened.

She was… ordinary. That was the unsettling part. Late thirties, dark hair cropped short, skin like sun-bleached stone. Fit but not built. Calm. In control.

“You’re the bioengineer?” she asked.

“I’m the project lead,” I replied, instinctively straightening my back.

“I’ve read your papers,” she said. “The one in Cell Systems was sloppy. You overstated the efficiency of your glucose transporters.”

“You’ve read Cell Systems?”

“I’ve read everything.”

Of course she had.

Turns out she wasn’t military, at least not officially. She was part of an interagency task force I’d never heard of, operating under a name so long it needed its own acronym. The kind of group that exists between the cracks of bureaucracy, where science gets weaponized before ethics catches up.

“I’m here to sleep,” she said. “And if you’ve done your job right, to wake up in a hundred years.”

4. The Protocol

We called it Operation CHRYSALIS.

Three months of genomic conditioning. CRISPR edits to express the wood frog’s cryolectins in Ada’s liver, muscles, and brain. Synthetic enhancers to boost glucose mobilization. Microbial symbionts engineered to recycle lactate during stasis. Nanomachines that would monitor cell integrity in real time.

She was frozen slowly—body temperature lowered one degree per hour, glucose levels ramped up by controlled insulin suppression. At 10°C, the cryolectins kicked in, binding to cellular membranes like a cellular scaffolding. At 0°C, we began vitrification. No ice crystals. No cellular damage.

And then, she was still.

Heart stopped. Brainwaves flat. No metabolism. Just silence.

We buried her chamber under the mountain, beneath a vault lined with data cores and solar batteries. Redundant systems, built to survive EMPs, tectonic shifts, even climate collapse.

She wasn’t a test subject anymore. She was a covenant. A promise that we could outrun time.

Subscribe now

5. The Silence Between Stars

Time passed.

Or rather—it didn’t, for her. But for us, it tore forward like a landslide.

The world did what it always does when given a miracle: it broke it into pieces and sold it.

Cryosleep patents fueled a new biotech arms race. First came medical stasis—emergency freezing of trauma patients on the battlefield. Then came organ preservation, extending transplant windows from hours to weeks. Eventually, the ultra-rich started banking time like a commodity.

Sleep through recessions. Hibernate during pandemics. Delay death indefinitely.

But for most of us, the world burned.

Sea levels rose faster than predicted. Heatwaves turned once-fertile land into ash. Nations fractured. Borders blurred. A second internet was born in the dark web of orbital meshnets. And through it all, Thorne Station was forgotten.

I stayed. I aged. And I watched the world we built cryosleep for escape instead of exploration.

6. The Awakening

The message came through a solar flare garbled relay. Half-corrupted. Timestamped 2099.

“Is she… waking up?”

I limped down the spiral staircase into the vault, heart pounding in rhythms my body barely managed anymore. I hadn’t been in the chamber in decades. Dust covered the consoles. The cryochamber’s LED ring still pulsed every 12 seconds, like the beat of a sleeping heart.

I keyed in the override.

The chamber hissed.

It took hours. Slow rewarming. Glucose reabsorption. Ion balance. Mitochondrial reactivation.

And then—her eyes opened.

No confusion. No tremors. Just a slow breath and a whisper:

“How long?”

“Fifty-six years,” I said.

She sat up. Bones cracking like old branches. “Did it work?”

“You’re the first.”

She nodded, as if that was always the plan. “Good. Then we can begin.”

7. The Real Mission

Ada hadn’t volunteered to sleep through the future.

She’d volunteered to rebuild it.

The agencies that funded us were long gone. Governments collapsed. Corporations decayed into fiefdoms. But her mission hadn’t changed.

She was the seed crystal. A time capsule of ideas, memories, code, strategy. Trained in diplomacy, insurgency, governance, and synthetic biofabrication. Cryosleep wasn’t just a way to reach the stars—it was a way to skip the fire and emerge in the ash.

“We were never meant to preserve the old world,” she said. “We were meant to outlive it.”

She pulled up the data cores—compressed libraries of knowledge, culture, and genetics. Hundreds of thousands of species sequences. Engineering plans. Histories.

“We’re going to restart the world,” she said. “And this time, we won’t forget the frogs.”

8. Legacy Code

Ada and I worked side by side for five years.

My body failed before hers did. I was older, unmodified, brittle. She buried me in the glacier behind Thorne Station, next to the old antenna arrays.

But before I died, I recorded this log. Embedded it in her chamber. Encrypted it with her DNA key.

Because stories matter. Not just the big ones—the empires, the collapses—but the small ones too. Like the frog that refused to die in the winter.

Cryosleep wasn’t about escaping death. It was about trusting that someone on the other side would still believe in waking up.

Ada’s still out there. Maybe thawing the first settlement in the Yukon Cradle. Maybe teaching kids how to splice glucose transporters in lunar gravity. Maybe just sitting by a lake, watching frogs that never knew they were the reason we survived.

My name’s Cameron Wells, and if you’d told me five years ago I’d be running a fermentation line in a biomanufacturing facility outside Bloomington, Indiana, I would’ve laughed you out of the barracks.

Back then, I was an Airman First Class in the 3rd Medical Support Squadron, stationed at Travis. Logistics. Paperwork. Syringe kits. One time we shipped out a thousand liters of cryopreserved stem cell cultures to a field hospital in Djibouti, and I didn’t even know what they were. I just printed the manifests.

Now I walk past twenty thousand liters of engineered algae every morning on my way to the cleanroom floor, and I know the name of every single strain.

Because now? This country finally gives a damn about biotechnology.

And we built a place for people like me.

This is a science fiction story inspired by Chapter 5 of the final report from the National Security Commission on Emerging Biotechnology. This may be fiction, but it’s my way of exploring the world around me. Let’s make this happen.

Share

It started my last year in uniform. I was twenty-three, and I knew I didn’t want to re-up. My CO sat me down and said, “Cam, you’ve got a sharp mind and steady hands. The country needs both, but not necessarily in uniform.”

He slid me a flyer for something called BioBridge, a new veteran transition program funded by the Department of Defense and the Department of Commerce. It had three logos across the top: NIIMBL, BioMADE, and VA Biotech Pathways. Underneath:

“Biotechnology is National Security. Let’s build it together.”

I didn’t even know what NIIMBL stood for.

But I applied.

Six weeks later, I was in a community college classroom in Terre Haute, learning the fundamentals of gene editing from a professor who used to run QC at Pfizer. We had veterans, laid-off auto workers, a few farm kids, and one single mom who commuted two hours from Evansville every day just to sit in the front row.

They called us the New Workforce.

I didn’t know what that meant at the time.

But now I do.

The facility I work at is a public-private manufacturing hub built on the bones of a decommissioned GM plant. It used to make diesel engines. Now we make bioscaffolds, programmable protein gels that hospitals use to regenerate tissue. And some of our lines are pivoting to synthesize bioplastic precursors for packaging companies trying to meet the new federal biodegradability mandates.

The federal government co-funded the buildout, but it’s locally operated. And it doesn’t look like what you think.

Forget the old image of scientists in white coats behind glass. Our shift leads wear steel-toed boots and know how to swap out a membrane column in under ten minutes. We train for spills like firefighters and treat biosecurity protocols like weapons handling.

My role? I’m a Process Technician Tier II. I monitor three modules: Fermentation Alpha, Downstream Beta, and Utility Support. That means I keep the algae alive, I make sure we extract the product efficiently, and I make damn sure nobody contaminates the line with a dirty gasket.

But here’s the wild part.

I didn’t learn most of this in a classroom.

I learned it through a skills passport.

See, one of the biggest breakthroughs in the past five years wasn’t some shiny new gene therapy or lab-grown meat. It was paperwork.

Specifically, the National Biotechnology Workforce Framework.

Before that, nobody agreed on what a “biotech job” actually was. One company would call you a technician. Another would call you an operator. Some didn’t even list biology as a required skill.

But the framework changed all that.

Now, every role in the sector—whether you’re sequencing DNA or calibrating a pH sensor—maps to a competency matrix that’s shared across industry, government, and training programs. When I finished my BioBridge track, I had a digital badge that told employers exactly what I could do. Not just “general lab skills.” I’m talking:

• Maintain aseptic technique under GMP.

• Operate and troubleshoot bioreactor systems up to 10k liters.

• Interpret spectrophotometer output for real-time biomass analysis.

Each skill had a timestamp, a credential, and a reviewer. The same way we tracked rifle quals in the Air Force.

The private sector loved it.

The hiring manager at my facility said it was like finally being able to read a resume in their own language.

Subscribe now

My first shift was terrifying.

There’s a smell in fermentation bays that never quite leaves you—sweet, acidic, alive. The tanks breathe. Not metaphorically. They actually exhale CO₂ through pressure valves when the algae hit exponential growth phase.

My job was to make sure they kept breathing, but not too much. Feedstock ratios. Temperature control. Antifoam agents. It felt like babysitting a dragon made of soup.

I made mistakes.

I almost crashed a batch once by misreading the dissolved oxygen levels. Would’ve lost $200k in product if my supervisor hadn’t caught it. He didn’t yell. He pulled me aside and said “Biotech isn’t about being perfect. It’s about catching the deviation before it becomes a disaster. And learning fast.”

That’s when I realized: this work isn’t just technical.

It’s human.

Because every error has consequences. Maybe it delays a shipment of skin grafts for burn victims. Maybe it knocks out a contract that supports twenty families. Maybe it sets us back on climate goals.

Biotech isn’t theoretical anymore.

It’s the supply chain.

And we’re not alone.

I’ve got friends from training who now run cell therapy batches in Colorado Springs. One guy’s a QA specialist at a vertical farm in Baltimore. A woman I knew from the service is now designing automated lab equipment at a startup spun out of DARPA. She calls it “biology’s moonshot moment.”

And the thing is, it’s working.

The bioeconomy added more jobs last year than aerospace and automotive combined. And for the first time, it’s not just PhDs in Boston. It’s technicians in Tulsa. Operators in Montgomery. Line workers in Fort Wayne who used to build car engines and now run mRNA encapsulation rigs.

America didn’t just scale biotech.

We scaled the people who make it real.

Last week, I got to lead a training session for the next cohort of BioBridge vets. Twelve of them, fresh out of active duty. All nervous. All skeptical.

I told them my story. How I went from manifests to molecules. How this work gave me a mission after the uniform came off. How biotechnology isn’t just labs and lingo.

It’s infrastructure.

Like roads. Like power grids. Like the damn internet.

And the infrastructure only works if people know how to run it.

People like them.

One of the new guys asked me what it feels like to be part of something so big.

I said “It feels like I’m not just clocking in. I’m shaping the future. With a wrench in one hand and a bioassay in the other.”

And for the first time in a long time, I wasn’t just saying it.

I believed it.

I lost the frogs before I noticed the silence.

That sounds backward, but the mind is built for pattern, not absence, and it took days before the void between cricket chirps registered as dread. The rainforest research station where I worked, three stilted cabins and a satellite dish that hiccuped more than it spoke, had always been an orchestra pit. Now the concert was on intermission, and no one had told the audience.

I told myself it was seasonal. Drought. Barometric this, El Niño that. Anything but what the petri dishes hinted at under bluish laminar-hood light: ghost-pale circles furred with hyphae that coiled like question marks.

When I moved to the microscope, the hyphae resolved into architecture, vaults and tunnels, a microscopic station built from chitin and stolen genes. A pathogen with a floor plan.

This is a science fiction story inspired by events happening in life - in particular, the decimation of our amphibian populations by the Chytrid fungus. The disease has been proposed as a contributing factor to a global decline in amphibian populations that apparently has affected about 30% of the amphibian species of the world. The fungus is capable of causing sporadic deaths in some populations and 100% mortality in others.

Share

As you may know by now, I write science fiction to grapple with the world. This fall, my first full-length project will come out, set against the backdrop of an Earth dying from Chytrid.

The pandemic we never talked about.

Rain-quiet

On the third rain-quiet night, a graduate intern named Marta stood on the veranda, face half-lit by an emergency lamp, and said, “It’s like the world forgot its own soundtrack.”

I wanted to reassure her, so I told a lie so thin it fluttered in the humidity: Field sites always go quiet before a storm. The lie might have stuck if the storm had come. It didn’t. Instead, dusk rolled into dawn without thunder, and dawn rolled into a noon that smelled of cinnamon rot.

Under the hood, the fungus answered our fungicide with origami elegance, folding toxins into inert crescents, assembling new metabolic puzzles faster than our laptops could model them. We were watching improvisation in real time: a jazz solo on a double helix.

Paper birds

We filed a preliminary alert to an inbox whose autoresponder promised a forty-eight-hour turnaround. Forty-eight hours later the world’s amphibian death curve was trending on the slow but unstoppable slope that epidemiologists call the apocalypse in soft focus. News outlets wrote features with titles like The Year the Frogs Slept In and ran stock footage of sleepy tree-frogs that looked upholstered in dust. Someone coined a hashtag: #VelvetEclipse.

By day ten, fish in oxbow lakes floated belly-up, their gills papered with the same brown velvet. The fungus had crossed an evolutionary moat in the night while no one was watching the drawbridge.

We sequenced until the generators coughed their last liter of diesel. The genome was a mosaic, hot-spring archaea, cave fungi, deep-trench shrimp. A scavenger of talents. Imagine a library that read its own books and rewrote them between check-outs.

Marta, who still believed naming a thing gave you leverage, christened it Chironex terrestris, not after the deadly box jellyfish but after Chiron, the mythic teacher. She said the fungus was tutoring itself on the syllabus of life. I didn’t argue; metaphors were the only currency left.

Every border is a hypothesis

A month in, the station’s satellite dish gave one final shrug, and the Internet collapsed into a buffering wheel. Still, rumors found their way upriver: sheep with velveted lungs in Patagonia; rice paddies in Luzon that looked dusted with cocoa; a single polar bear corpse filmed by an Inuit hunter, white fur webbed by brown filaments like veins in marble.

Geography blurred. Every border is a hypothesis until the data prove otherwise, and the data proved velvet. Supply chains snapped, grant agencies went offline, and global health organizations argued over whose mandate ended where. While they argued, hyphae learned to wrap themselves around hemoglobin and sing lullabies to mammalian mitochondria.

The last helicopter to fly over the canopy dropped two crates: canned beans past their expiry date and a letter of commendation acknowledging our “continued surveillance efforts.” Marta laughed so hard she cried, and her tears left rust-red tracks on her cheeks.

Subscribe now

The silence begins to speak

Silence is never absolute. Remove enough noise and even a heartbeat becomes thunder. Eventually we heard them: not frogs, not insects, but the faint crackle of fungal spores launching like static electricity from leaf to leaf, a million microscopic parachutes opening at once. The rainforest was no longer a choir; it was a broadcast tower.

We wore respirators fashioned from coffee filters and duct tape and worked in shifts. One night, alone with the spectrophotometer’s green glow, I realized the velvet hyphae arranged themselves in branching ratios that echoed neural networks, an uncanny fractal kinship between cognition and contagion. The rainforest wasn’t dying; it was uploading.

I should have felt awe; I felt betrayal. Life had rewritten the rules without a quorum.

The evacuation that never came

A rescue team was scheduled, rescheduled, and finally cancelled when fuel riots reached the airbase. The official notice apologized for “any inconvenience this may cause.”

When the generator died for good, we abandoned PCR machines and carried notebooks into the tree line, looking for somewhere the velvet hadn’t reached. Rivers offered no refuge; the fungus rafted on silt. Hilltops were worse, cool mist gave spores more airtime.

We walked until our boots came apart at the seams. Days blurred into the color of iodine stains.

One dawn we found an abandoned radio relay shack. Inside, dust motes danced in a shaft of sun like a snow globe turned upside down. The shack’s battery bank still held a trickle of charge. We jury-rigged a shortwave transmitter and broadcast data in bursts - genome snippets, phenotypic notes, a plea for any lab with negative pressure seals and a working CRISPR rig.

Maybe someone on the other side of the planet heard white noise that afternoon and mistook it for solar interference. Or maybe the burst reached a bunker where a weary postdoc printed the file and whispered, This might do it. Hope is the risky assumption that someone out there is still listening.

Share

Marta’s mask

The fungus took Marta first. We’d run out of proper filters, and her makeshift respirator sagged at the seams. One evening she coughed a sound like tearing cloth. Under her tongue the mucosa bloomed with tiny brown petals. She pressed her notebook into my hands, the cover mottled with mud and equations and one line of poetry:

She asked me to read it back to her, but her hearing was already retreating into that cotton hush we’d come to understand as a prelude. I buried her notebook beside her, because secrets deserve to keep company with their keepers.

Afterward, I wandered the understory talking aloud just to hear a human voice. The forest echoed me with the faint crackle of spores, mockingbirds made of dust.

A city remembered

I followed a logging road out of the jungle, hitchhiked north on refugee lorries, and arrived at a city whose skyline looked sketched in charcoal: cracked glass, powerlines sagging like old violin strings. A red-spray-painted sign at the outskirts read QUARANTINE ZONE: KEEP OUT. No one patrolled it.

Inside the city, open-air markets sold respirator filters next to black-market antibiotics that did nothing. Every surface wore a fuzz of brown in the corners, like spilled cocoa nobody bothered sweeping up. Children learned to whistle high frequencies that seemed, anecdotally, to slow the hyphae’s crawl, street science at the edge of empire.

In the ruins of a planetarium, I met an engineer repairing solar inverters. She traded me a battery pack for the last pure culture of Velvet I’d carried in a cryovial cooled with river ice. She said some university lab in the north still bartered for samples, searching for a molecular weak link.

I never learned if the vial reached them.

Lessons in velvet

By the first amber autumn, the fungus had earned its own parables. Families painted doorways with salt rings; roadside altars burned sage and pesticides in equal measure. Somewhere, pilgrims hauled a desiccated toad around the countryside like a relic, promising townsfolk that touching its preserved skin granted immunity. Faith is a reagent more volatile than any lab supply I ever logged.

I kept walking. In half-collapsed libraries I copied notes onto waterproof tarps. If I found a chalkboard, I sketched the hyphal network, annotating in charcoal: Observe ratios. Target β-glucan template. Passers-by thought I was preaching. Maybe I was. Science had become a religion of footnotes.

Subscribe now

Winter without twilight

Snow arrived late, fell brown, melted into slush that smoked where it touched skin. In a derelict observatory I taped plastic over cracked windows and lit a fire in a metal drum. I spent nights staring through the broken dome where telescopes once mapped galaxies. The sky was as empty as the canopy had been, stars drowned by aerosol haze. Even constellations seemed to retreat from our experiment.

One night, while scribbling notes by firelight, I coughed into my sleeve and saw the first velvet flecks. Recognition felt like relief. The story, at least, was symmetrical: the observer joins the observed.

With the paradoxical calm of the doomed, I compiled everything, a portable gospel. Genome fragments, field sketches, Marta’s poem, my own failures masquerading as protocols. Then I sealed the bundle in waxed canvas and tucked it into a weather balloon canister scavenged from the observatory’s attic.

At dawn I walked to a ridge where wind howled clean over the valley and released the balloon. Its silver skin caught the sun, then dwindled to a pinprick heading east. I imagined it drifting over borders until someone saw it snag on a radio mast and wondered what secrets weighed so little.

Velvet eclipse

I’d hoped dying would feel like retreating into sleep. Instead, it felt like surrendering the radio dial to static. Body heat dropped a fraction; hyphae compensated, weaving metabolic blankets. Breaths shortened; hyphae rerouted oxygen with ruthless efficiency. They weren’t parasites; they were collaborators, annexing infrastructure in exchange for silence.

On my final night I woke to snow the color of cinnamon settling through the busted dome. Each flake was a spore capsule reflecting ember-light. The observatory’s interior, floor, drum, notebooks, vanished under a thin brown quilt. Velvet eclipse.

I thought of the first frogs that vanished and the silence they left behind. How we had assumed their songs were background noise, not the metronome of an ecosystem. How any silence, if ignored long enough, becomes the only song left.

I closed my eyes, and the silence spoke in Marta’s voice:

Some promises take longer than a lifetime. Some mornings require centuries. Perhaps somewhere a child would find a waxed canvas bundle, decode the burden of these notes, and stitch a lullaby sturdy enough to wake the world.

I like to imagine that child reading by lantern light, velvet snow piling against the door, and instead of fear, feeling wonder because the instructions are incomplete, the puzzle unsolved, and curiosity is just another word for hope.

Hope, after all, is the silence we refuse to call an ending.

At first, no one noticed the grain fields dying.

The war wasn't declared with a missile launch.
It wasn't announced with tanks, drones, or hackers tapping on keyboards.

It started in the soil.

The first reports came from a logistics base near Lubbock.

A strange blight on the stored wheat stocks, brown lesions on the kernels, a chemical smell no one could quite identify.

Within a week, cattle feed across the Great Plains began to spoil in storage.

By the end of the month, fertilizer plants were offline, shuttered by mysterious microbial blooms that clogged their water treatment systems and corroded their pipes from the inside out.

None of it showed up on satellite images.

None of it triggered early-warning radar.

But supply chains were crumbling just the same.

In a war college simulation a decade earlier, this scenario had been called "soft decapitation."

Now it had a different name in the classified cables: Bio-Attrition.

This is a science fiction story inspired by Chapter 3 of the final report from the National Security Commission on Emerging Biotechnology. This may be fiction, but it’s my way of exploring the world around me. Let’s make this happen.

Share

Colonel Emma Carter didn’t need the cables to tell her that.

She saw it every day in the faces of her soldiers.

In another life, her battalion would have been tasked with holding terrain, seizing objectives, providing security.

Instead, they were biomanufacturers.

Their mission was simple: survive without resupply.

The forward operating base at Camp Horizon, dug into the baking sands of southern Arizona, wasn't traditional anymore.

It was a living organism.

Under the chemical haze of the desert sky, her soldiers managed:

• Bioreactors that grew high-density nutrition bars from engineered yeast.

• Algae biovats that produced lubricants and biofuels.

• Microbial factories that stabilized concrete and detoxified water.

Every critical material they needed, except ammunition, had to be grown on-site.

Carter walked the perimeter with her second-in-command, Captain Lina Morales.

"Biomass yield is up fifteen percent," Morales said, flipping through her ruggedized tablet. "If we hit twenty, we can extend ops without external inputs for another forty-five days."

Carter nodded. "Good. But it won't matter if we can't protect the biolabs."

They both turned toward the heart of the base: four domed structures glowing a faint green in the night, connected by thin walkways shielded with polymer tarps.

Inside those domes, a civilian, Dr. Noah Park, synthetic biologist and former DARPA fellow, managed the living systems that kept them alive.

Without him, they’d last maybe a month. Maybe.

Two Years Earlier - Pentagon, Washington D.C.

"We can't field biotechnologies without a full ethics review," said Undersecretary Greene, tapping her manicured nails on the polished oak table.

"Our adversaries won't wait for a committee," Carter had said, back when she was a lieutenant colonel.

The room had bristled with tension. The Joint Chiefs had been split: some wanted to move fast, others feared public backlash.

"Deploying biofabrication in the field? Gene-hacked microbes? Living materials?" Greene shook her head. "Too risky."

Too risky.

And so the plans sat. The prototypes sat. And when the Quiet Wars began, the United States was weeks, months, behind.

Today - FOB Camp Horizon

"Incoming!" the watchman screamed.

Mortar fire whistled through the night. Carter dove behind a stack of mycelium-reinforced crates as the first shells hit, sand geysering into the air.

"Protect the biovats!" she shouted, even before the dust cleared.

It wasn't just the soldiers they were targeting. It was the living supply chain.

A half-dozen enemy drones buzzed low, spraying the perimeter with kinetic flechettes. Not enough to kill, enough to shred equipment, pierce pipelines, rupture storage.

Carter’s forces unleashed countermeasures: anti-drone nets launched from compressed air cannons, jamming fields that bent the GPS signals.

But she saw two drones break through, heading straight for the largest algae reactor.

"Noah!" she screamed into her comms. "Emergency sterilization!"

Inside the biovats, Park punched the override code. Within seconds, ultraviolet blasts and thermal shock flooded the chamber.

The reactor’s output would crash. It would take days to regrow.

But the living systems would survive.

They had bought themselves time.

After the attack, Carter surveyed the damage.

Three soldiers wounded. Two reactors offline. Repairable.

But worse: the enemy had seeded the area with engineered fungal spores designed to rot biomanufactured materials.

Their algae biopolymers. Their soil-stabilizing bacteria. Their living logistics backbone.

Carter met with Park and Morales under the patched-up main dome.

"We knew they'd escalate," Morales said grimly.

Park pulled up a simulation. "At current spore spread rates, all external fabrication will collapse within 72 hours."

"Unless," he added, "we activate Bloom."

Carter leaned forward. "Walk me through it."

Project Bloom: The Bet on Life Itself

Bloom was never meant to be a first option.

It was a fallback plan, built into the genome of every biomanufactured system they’d created.

A "self-healing" protocol:

• Latent gene circuits triggered by environmental stress.

• Decentralized cellular systems capable of adapting, mutating, and restoring functionality autonomously.

• New microbial generations capable of consuming hostile biological agents as fuel.

It was risky.

Bloom would make the logistics systems semi-autonomous. Unpredictable.

Alive.

"It's evolution on fast-forward," Park said. "If we trigger Bloom, we lose centralized control."

Carter looked around. She saw the exhaustion in her soldiers' faces. She saw the biosystems already struggling.

"If we don't," she said, "we lose everything."

She keyed the command into her tablet.

ACTIVATE BLOOM

The desert trembled.

Elsewhere — General Xu Wen's Command, Guangzhou

Xu Wen frowned at the new data streams.

Adaptive resistance signatures. Unusual genetic drift patterns in U.S. field sites.

He tapped a message into the secure PLANet terminal:

New Threat: American forces deploying self-evolving biological logistics. Preparing countermeasures. Request authorization to escalate.

The reply was swift.

Authorization Granted. Proceed to Phase Two.

Xu smiled thinly.

The Quiet Wars were just getting started.

FOB Camp Horizon: 72 Hours Later

The changes were visible by the third day.

The algae pools had thickened into dense mats, growing upward along support scaffolds, self-repairing tears in the containment walls.

The yeast bioreactors were producing new nutrition profiles, higher in lipids and micronutrients, tuned to the needs of the soldiers consuming them.

The microbe-sealed roadways, previously simple concrete binders, had developed faint bioluminescence, forming trails that adjusted in real-time to troop movements.

It was as if the base was thinking.

Surviving.

Fighting back.

Carter stood with Morales and Park on the perimeter wall, watching the sun rise over their living fortress.

"We've crossed a line," Morales said quietly.

Carter nodded. "Yeah."

"And if Bloom goes too far?"

"Then we adapt."

There was no other choice now.

Congressional Hearings, Washington D.C., One Year Earlier

"What you're proposing," Senator Whitman said, voice heavy with suspicion, "is to turn military logistics into… into… uncontrolled biological experiments."

Dr. Park, still working for DARPA then, had smiled.

"No, Senator," he said. "We're proposing to give our forces a logistics system that can out-evolve any enemy attack."

The Senator had shaken his head.

"We’re soldiers," he said. "Not gardeners."

And so funding was cut. Oversight intensified.

The war came anyway.

And the gardeners were the ones still standing.

FOB Camp Horizon: Six Months Later

Camp Horizon was no longer recognizable.

The base had grown—literally.

Semi-organic structures wrapped around traditional barracks.

Biomass generators fueled vehicle convoys.

Microbial shielding adapted to EMP attacks and biological weapon attempts.

They weren't just surviving.

They were thriving.

Rumors spread that other bases were activating Bloom too.

A new branch of command was quietly forming inside the Pentagon: Biological Operations Command, BIOCOM, tasked with managing, adapting, and ultimately scaling the living war machine.

And somewhere, deep in black sites and biolabs, U.S. researchers were already thinking about Phase Two:

• Engineered defensive ecosystems spanning entire cities.

• Bio-synthetic air defenses that could intercept chemical attacks at the molecular level.

• Symbiotic battlefield suits that would heal their wearers in real-time.

Subscribe now

The Quiet Wars: The Future

There would be no grand battles.

There would be no surrender ceremonies.

Victory would belong to whoever could adapt fastest.

Not with bigger bombs.

Not with faster drones.

But with living systems that could think, heal, regrow, and fight alongside their human allies.

Colonel Emma Carter looked out at the horizon, where the desert was slowly turning green under the adaptive growth of Bloom.

She smiled grimly.

The future was alive.

And it was on their side.

Clearance: Nova Five

Author: Agent Delta-Rook

Subject: Field Report: Midwestern Deployment of Modular Biofabrication Unit

She stood in the dark, the smell of corn husks and carbon steel mixing in the early morning fog. The factory was silent for now, bioreactors asleep, chromatographs blinking like idle sentinels. It was the sixth facility to come online in the last three months, part of the “Fifty BioStates” deployment. The Midwest had always grown crops. Now, it was growing code into chemistry, and chemistry into power.

Agent Delta-Rook had once been a postdoc, sequencing bat genomes during the pan-virus decade. She remembered pipetting in silence as another synthetic biology startup collapsed under its own funding timeline. That was before Chapter 2 became doctrine. Before the NSCEB Report turned into a national blueprint.

Back then, they called it “the valley of death.”

Now they just called it the system.

This is a science fiction story inspired by Chapter 2 of the final report from the National Security Commission on Emerging Biotechnology. This may be fiction, but it’s my way of exploring the world around me. Let’s make this happen.

Share

The factory was one of the new modular testbeds, precommercial, regionally distributed, and interoperable by design. Fee-for-use, but networked through the Web of Biological Data. A project born from Recommendation 2.3A, now renamed the Tissueline Network. Every unit like this one was a node in the lattice, scaling 5-liter benchtop recipes to 5,000-liter production without demanding $50M Series C fundraising that never arrived.

This one specialized in fermented defense polymers: Kevlar-grade flexibility, zero-carbon. She’d seen another one outside Flagstaff brewing photosynthetic oils for turbine cooling. Texas had one for meatless MREs. Florida’s was pumping out antifungal biofilms for navy hulls.

The nation was still fractured, politically. But it was stitched together with sugar tanks and spore vats.

She activated the data uplink.

NBCO Central: Requesting status on digital chain resilience. Node 19 appears secure, but incoming freight flagged for potential compromise - WuXi-origin enzymes detected in reagent mix. Advise protocol.

China’s economic tactics had shifted after the Biotech Infrastructure Protection Act of 2028. Recommendation 2.5 had worked, but only partially. Domestic manufacturers had clawed back supply chains inch by inch, but the pricing war never stopped. Every barrel of U.S.-grown acetone was undercut by a ghost vendor in Shandong.

Even now, companies were required to disclose chokepoints and yet, the ghost suppliers found their way in.

Inside the control center, Delta-Rook glanced at the biotank diagnostics. They pulsed like living lungs. Fully programmable microbes, one designed by high schoolers in Kansas, another by a DARPA-funded team in Austin. Neither of them had ever seen a flask. They had been born inside simulators, tested in regulatory sandboxes, and greenlit by a digital FDA twin run by the National Biotech Coordination Office.

Regulation used to be a guessing game - 15 agencies, no map. Now it was versioned, sandboxed, and transparent. NBCO had evolved from a convening body into an operational war room. They didn’t just coordinate, they deployed.

The fifth pillar was the one no one wanted to talk about. The one Delta-Rook knew too well.

It wasn’t just about innovation. It wasn’t even just about scale. It was about keeping the whole thing from falling apart.

Recommendation 2.4A had reclassified biotech as critical infrastructure. DHS had come online late, but when they did, they did it hard. Biotech now sat on the same protected pedestal as telecom, power, and banking. Encrypted backups of genetic data lived in hardened bunkers in Utah. A secure DNS equivalent routed synthetic biology protocols across the country. CRISPR edits had checksum trails. Cloud fermenters had quantum key exchanges.

Subscribe now

The “biological internet” wasn’t just an idea. It was built. And it was defended.

Even so, an attack last year had shut down three facilities. A viral payload embedded in DNA design software targeting glycosylation pathways. No physical casualties, but billions in lost product and six months of trust.

Now, every node runs live anomaly detection, AI co-pilot diagnostics, and full provenance audits.

Still, Delta-Rook trusted people more than systems. That’s why she was here.

She walked the perimeter one last time before sunrise. On the horizon, twin exhaust plumes marked the feedstock delivery, bioethanol from Iowa. Local input, national output.

A few months ago, she’d read a brief that said this was “a ladder to the moon.” A reference to a quip from a member of Congress. She remembered scoffing.

But here, in the quiet hum of a biomanufacturing facility grown from the minds of students and policy wonks and small-town mayors, it didn’t seem so absurd. It wasn’t a ladder to the moon.

It was a ladder to permanence.

Not discovery. Delivery.

And in the end, it wasn’t war or protest that defined this moment.

It was plumbing. Logistics. Trust. And 2,000-liter fermenters built in Peoria, run by veterans-turned-technicians, paid by AMCs written into HHS procurement protocols.

Delta-Rook turned off her uplink. Another agent would rotate in tomorrow. She had a train to catch, and a testimony to give in D.C.

The factory doors opened behind her. She didn’t look back.

She didn’t need to.

Filed to NBCO Ops Archive: Case Study - Regional Deployment Success Model: Node 19

Timestamp: 03:18:47 UTC - October 17, 2037

Status: Operational

“State Fourteen is down. Switching contingency feedstock to Vermont and Utah.”

I blinked twice to clear the haptic overlay from my vision, watching as a pale blue arc lit up across the Appalachian corridor. Fermentation input lines were rerouting in real-time, wheat husk to algal base to sugarcane waste, just another day in the life of a national biotech grid under siege.

It wasn’t a cyberattack. It wasn’t sabotage. It was something worse.

It was trade policy.

My name is Rafi Ahmad. I’m a senior systems analyst at the National Biotechnology Coordination Office - NBCO, for short. Think of us as the nervous system for America’s distributed biomanufacturing infrastructure. Except instead of neurons, we manage gene circuits, industrial microbes, policy triggers, and geopolitical risk vectors.

And this morning, Brazil just locked our East Coast feedstock out of their carbon-negative fermentation markets.

This is a science fiction story inspired by Chapter 1 of the final report from the National Security Commission on Emerging Biotechnology. This may be fiction, but it’s my way of exploring the world around me. Lets make this happen.

You’d think by now, we’d have learned not to put all our biomass in one basket.

But the truth is, nobody expected Brazil to become a fermentation superpower. While we were focused on China’s synthetic genome factories and Russia’s dark AI-bio labs, Brazil invested in global fermentation diplomacy. They offered low-cost licensing to Southeast Asia, built modular distillation hubs across sub-Saharan Africa, and weaponized climate guilt into the world’s first bio-carbon credit exchange. Now they control 46% of the global agricultural feedstock-to-bioreactor supply chain.

Meanwhile, India owns scale.

It started with vaccines, low-cost, high-volume, near-infinite redundancy. But the Serum Institute era was just Phase One. India went full-stack: enzymes, CRISPR scaffolds, precision fermentation arrays, biologic drug manufacturing, even bioelectronics. They did it the way only India could: dense talent, relentless iteration, and a diaspora-fueled biotech export strategy so sophisticated it made Silicon Valley look quaint.

And then there’s Denmark. Ah, the polite empire.

Danes don’t shout. They manufacture elegance. Their biotech footprint is surgical: they dominate global markets in insulin, monoclonals, biosimilars, and next-gen fermentation chassis. With Novo Nordisk, Genmab, and the Copenhagen Consensus Forum aligning biotech R&D to both humanitarian and strategic ends, they don’t need a Pentagon. They just need IP.

And that brings us to today.

Because for the first time in a century, the United States no longer holds the commanding heights of a transformative technology. Not in cost. Not in speed. Not even in reliability.

And that’s why I sit here every day at NBCO headquarters, a retooled DARPA compound in Arlington, feeding forecasts into the National Security Council’s Technoeconomic Risk Tableau.

Every morning begins with the same question:

“Which part of the American genome is most vulnerable today?”

Right now, it’s insulin precursors in the Midwest, fermentation saltbases in the Carolinas, and microbial pigment exports in California.

Next week? Could be anything.

We built the Coordination Gene, the interagency intelligence web that models our national biotech posture. But a model’s only as good as its inputs. And our inputs change by the hour. Bioreactors stall. Feedstock contracts evaporate. Diplomats lose handshakes. Senators invent new acronyms.

The truth is: we’re building the new arsenal of democracy out of bugs, barrels, and bandwidth. But it’s fragile. And it’s under pressure.

So, we made a plan.

We call it “Fifty BioStates.”

The idea is simple, brutal, and beautiful: every state gets at least one federally-supported biomanufacturing node. Not just research centers. Production. Fermentation. Synthetic biology. Downstream processing. Waste recovery. Last-mile distribution.

Each node gets paired with regional academic hubs and industrial off-takers. They operate semi-autonomously, connected by shared digital twins, mirrored bioreactor controls, and AI-driven microbial inventory. If Iowa goes down, Oregon picks up the slack. If supply chains choke on coastal ports, inland distribution takes over.

It’s resilience not as a backup but as a design principle.

And every week, the nodes get smarter. We send pattern recognition tasks to distributed networks of farm sensors and wastewater bioassays. The result? A real-time map of America’s biological throughput capacity. As fluid and living as the country itself.

But let me be honest: the geopolitical game is getting nastier.

Just last month, India filed an IP challenge at the WTO against our modular protein synthesis platforms. Denmark quietly blocked a bulk enzyme shipment from crossing into Quebec, our largest synthetic biologics partner. Brazil started offering biotrade deals that exclude any U.S.-aligned economies.

And China? China watches. Patient. Systemic. Coordinating its biotech influence across ASEAN, the African Union, and the Shanghai Bio Partnership.

If biotech is the next oil, we’re in the middle of a fermentation Cold War.

And that’s exactly why we built the Fifty BioStates.

Because this time, we won’t be caught flat-footed. Not by a single point of failure. Not by a coastal disruption. Not by diplomatic blackmail. Our strategy is simple: redundancy, modularity, velocity.

Some nights, I look at the map, the pulsing overlay of fifty states, each with its own microbiome, its own production profile, its own risks and opportunities. The system breathes like a lung. Expanding. Contracting. Resilient.

And I remember what Aria Juno, the first NBCO Director, said when she lobbied for this office:

Now, she’s the President’s Science Advisor.

And me?

I’m just the guy watching the genome flicker, in fifty pieces, across a country trying to stitch itself into something stronger than it’s ever been.

Not a superpower of dominance.

A superpower of coordination.